Conditions:   Colorectal Neoplasms;   Digestive System Diseases;   Colonic Diseases;   Colorectal Cancer
Intervention:  
Sponsors:   Exact Sciences Corporation;   Exact Sciences Corporation
Recruiting - verified May 2012

Condition:   Breast Cancer
Intervention:  
Sponsors:   Genentech;   Genentech;   23andMe, Inc.
Recruiting - verified May 2012

Conditions:   Acute Lymphocytic Leukemia;   Acute Myelogenous Leukemia;   Burkitt's Lymphoma;   Follicular Lymphoma;   Hodgkin Lymphoma;   Mantle Cell Lymphoma
Interventions:   Drug: Biological/Vaccine: Haploidentical BMT;   Drug: Double Cord Blood Transplantation
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network
Not yet recruiting - verified May 2012

Condition:   Mantle Cell Lymphoma
Intervention:   Drug: Ibrutinib
Sponsors:   Janssen Research & Development, LLC;   Janssen Research & Development, LLC
Not yet recruiting - verified May 2012

Conditions:   ALL;   B Cell Lymphoma;   Leukemia;   Large Cell Lymphoma;   Non-Hodgkin Lymphoma
Intervention:   Genetic: Anti-CD 19 CAR Autologous PBL
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Neoplasms, Hematologic
Interventions:   Drug: 200 mg LY2784544;   Drug: 400 mg LY2784544;   Drug: 600 mg LY2784544
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Not yet recruiting - verified May 2012

Condition:   Pancreatic Cancer
Interventions:   Drug: Cyclophosphamide;   Biological: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1/GM-Neo vaccine;   Radiation: Stereotactic Body Radiation (SBRT);   Drug: FOLFIRINOX
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting - verified May 2012

Conditions:   Cervical Cancer;   Oropharyngeal Cancer;   Vaginal Cancer;   Anal Cancer;   Penile Cancer
Interventions:   Drug: Fluderabine;   Drug: Cycolphosphamide;   Biological: Young TIL;   Biological: Aldesleukin
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Metastatic Cancer;   Melanoma
Interventions:   Drug: Vemurafenib;   Drug: Young TIL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Metastatic Cancer;   Pancreatic Cancer;   Mesothelioma
Interventions:   Drug: Fludarabine;   Drug: Cycolphosphamide;   Biological: Aldesleukin
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Solid Tumors;   Lymphoma
Intervention:   Drug: PU-H71
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: Cytarabine consolidation;   Drug: Cytarabine vs BMT
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting - verified May 2012

Conditions:   Ovarian Cancer;   Endometrial Cancer
Interventions:   Biological: E39 peptide vaccine;   Other: Clinical tracking for disease progression/recurrence
Sponsors:   San Antonio Military Medical Center;   COL George Peoples, MD, FACS
Recruiting - verified April 2012

Condition:   Mesothelioma
Intervention:  
Sponsors:   Wake Forest University;   Wake Forest University;   University of Pennsylvania;   Mayo Clinic;   New York University School of Medicine;   Johns Hopkins University;   Mount Sinai School of Medicine;   Memorial Sloan-Kettering Cancer Center;   Mesothelioma Applied Research Foundation, Inc.
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Drug: abiraterone acetate;   Drug: prednisone;   Drug: veliparib
Sponsors:   National Cancer Institute (NCI);   University of Chicago;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Patients Must Have Histologically or Cytologically Confirmed Non-squamous Cell, Non Small Cell Carcinoma of the Lung.;   Patient Must Have Measurable Stage IV Disease (Includes M1a, M1b Stages or Recurrent Disease).
Interventions:   Drug: Paclitaxel, Carboplatin, Bevacizumab, and Metformin;   Drug: Paclictaxl, Carboplatin, and Bevcizumab.
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Carcinoma;   Lymphoma
Intervention:   Drug: rh IL-15
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Leukemia
Interventions:   Drug: sorafenib tosylate;   Genetic: gene expression analysis;   Genetic: polymerase chain reaction;   Genetic: western blotting;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Carfilzomib;   Drug: Lenalidomide;   Drug: Dexamethasone
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Solid Tumors;   Lymphoma
Intervention:   Drug: Imetelstat
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Multiple Myeloma;   Smoldering Multiple Myeloma;   Monoclonal Gammopathy of Undetermined Significance
Intervention:   Drug: Fluciclatide
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Myelodysplastic Syndrome (MDS);   Hematologic Neoplasms;   Hematologic Diseases;   Severe Aplastic Anemia
Intervention:   Procedure: Cord Blood Transplant
Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2012

Conditions:   Prostatic Neoplams;   Prostate Cancer;   Neoplasm, Prostate;   Neoplasm,Prostatic
Interventions:   Drug: AMG 386;   Drug: Abiraterone;   Drug: Prednisone
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Breast Cancer;   Colon Cancer
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified November 2011

Condition:   Solid Cancers
Intervention:   Drug: Vismodegib
Sponsors:   Genentech;   Genentech
Not yet recruiting - verified March 2012

Condition:   Plasma Cell Myeloma
Interventions:   Drug: Filgrastim;   Drug: Plerixafor;   Procedure: Apheresis
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified January 2012

Conditions:   Formaldehyde;   Hematotoxicity;   Leukemia
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified December 2011

Condition:   Neoplasms
Interventions:   Drug: 5-Fluoro-2-Deoxycytidine;   Drug: Tetrahydrouridine
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified January 2012

Conditions:   Peripheral Neuropathies;   Multiple Myeloma
Intervention:   Device: Acupuncture
Sponsors:   University of Maryland;   University of Maryland
Recruiting - verified February 2012

Condition:   Lung Cancer
Interventions:   Drug: linsitinib;   Drug: topotecan hydrochloride
Sponsors:   National Cancer Institute (NCI);   H. Lee Moffitt Cancer Center and Research Institute;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Locally Advanced HER2-Negative Breast Cancer
Interventions:   Drug: Eribulin Mesylate;   Drug: Cyclophosphamide;   Drug: Docetaxel
Sponsors:   Sarah Cannon Research Institute;   Sarah Cannon Research Institute;   Eisai Inc.
Not yet recruiting - verified March 2012

Condition:   Cancer
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified November 2011

Condition:   Relapsed or Refractory Acute Myeloid Leukemia With FLT3-D835 Activating Mutations
Intervention:   Drug: Crenolanib Besylate (CP-868,596-26)
Sponsors:   Arog Pharmaceuticals LLC;   Arog Pharmaceuticals LLC
Not yet recruiting - verified January 2012

Conditions:   Myelodysplastic Syndrome (MDS);   Chronic Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   CML (Chronic Myelogenous Leukemia;   CLL (Chronic Lymphocytic Leukemia);   Acute Myeloid Leukemia (AML)
Intervention:   Procedure: Stem Cell Transplantation
Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified August 2011

Condition:   Adenocarcinoma of the Prostate
Interventions:   Radiation: Radiation Therapy;   Drug: Androgen Suppression Therapy
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting - verified April 2012

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: temozolomide;   Drug: veliparib;   Genetic: gene expression analysis;   Genetic: protein analysis;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   National Cancer Institute (NCI);   Pediatric Brain Tumor Consortium;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Prostate Cancer;   Castration Resistant Prostate Cancer;   Pain;   Prostatic Neoplasms
Interventions:   Drug: cabozantinib;   Drug: mitoxantrone;   Drug: prednisone
Sponsors:   Exelixis;   Exelixis
Recruiting - verified April 2012

Condition:   Solid Tumors
Intervention:   Biological: GI-6301
Sponsors:   GlobeImmune;   GlobeImmune;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   Malignant Melanoma
Intervention:   Drug: vemurafenib
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Not yet recruiting - verified May 2012

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Veliparib;   Drug: Temozolomide;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Placebo
Sponsors:   Abbott;   Abbott
Recruiting - verified May 2012

Condition:   Liver Cancer
Interventions:   Drug: RO5137382;   Drug: Placebo
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified May 2012

Conditions:   Rhabdomyosarcoma and Other Soft Tissue Sarcomas;   Ewing's Sarcoma Family of Tumors;   Osteosarcoma;   Neuroblastoma;   Brain Tumors
Interventions:   Drug: sorafenib;   Drug: irinotecan
Sponsors:   Children's Research Institute;   Children's Research Institute
Recruiting - verified January 2012

Conditions:   Head and Neck Cancer;   Kidney Cancer;   Liver Cancer;   Sarcoma
Interventions:   Drug: sorafenib tosylate;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Other: enzyme-linked immunosorbent assay;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Uterine Fibroids
Interventions:   Device: MR-HIFU treatment for ablation of uterine fibroids;   Device: Sham HIFU treatment
Sponsors:   Philips Healthcare;   Philips Healthcare
Not yet recruiting - verified May 2012

Conditions:   Astrocytoma;   Glioma
Intervention:   Drug: 5-Aminolevulinic Acid
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting - verified December 2011

Conditions:   Advanced NET of GI Origin;   Advanced NET of Lung Origin;   Neuroendocrine Tumors
Interventions:   Drug: Everolimus;   Drug: Everolimus Placebo
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Conditions:   Diabetes;   Cancer;   Heart Disease
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Human Genome Research Institute (NHGRI)
Recruiting - verified October 2011

Conditions:   Mestatic Melanoma;   Skin Cancer
Interventions:   Drug: Fludarabine;   Drug: Cycolphosphamide;   Drug: Aldesleukin;   Drug: MART-1 Reactive CD8+ PBL
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Diffuse Large B-Cell Lymphoma
Interventions:   Drug: Fostamatinib;   Drug: Fostamatinib
Sponsors:   AstraZeneca;   AstraZeneca
Recruiting - verified May 2012

Conditions:   Breast Neoplasms;   Endocrine Breast Diseases;   Neoplasm Metastasis
Interventions:   Drug: letrozole;   Drug: lapatinib;   Drug: everolimus
Sponsors:   University of Maryland;   University of Maryland;   Novartis Pharmaceuticals;   GlaxoSmithKline
Not yet recruiting - verified December 2011

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: GDC-0941;   Drug: carboplatin;   Drug: paclitaxel;   Drug: bevacizumab;   Drug: Placebo
Sponsors:   Genentech;   Genentech
Recruiting - verified February 2012

Condition:   Prostate Cancer
Intervention:   Drug: 18F-DCFBC
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified December 2011

Conditions:   Locally Recurrent Breast Cancer;   Metastatic Breast Cancer
Interventions:   Drug: NKTR-102;   Drug: Treatment of Physician's Choice (TPC)
Sponsors:   Nektar Therapeutics;   Nektar Therapeutics
Recruiting - verified April 2012

Conditions:   Leukemia;   Leukemia, Lymphocytyc;   CLL (Chronic Lymphocytic Leukemia);   SLL (Small Lymphocytic Lymphoma)
Intervention:   Drug: PCI 32765
Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified October 2011

Condition:   Sarcoma, Kaposi
Intervention:   Drug: Pomalidomide
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified December 2011

Condition:   Breast Cancer
Interventions:   Drug: pertuzumab;   Drug: trastuzumab;   Drug: Aromatase Inhibitor;   Drug: Induction Chemotherapy
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified May 2012

Conditions:   Prostate Cancer Metastatic;   Hormone Refractory Prostate Cancer
Interventions:   Biological: sipuleucel-T;   Drug: abiraterone acetate
Sponsors:   Dendreon;   Dendreon
Recruiting - verified May 2012

Conditions:   Metastatic Colorectal Cancer;   Colorectal Cancer
Interventions:   Drug: MORAb-004;   Drug: Placebo
Sponsors:   Morphotek;   Morphotek
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Drug: kanglaite gelcap;   Drug: Kanglaite gelcap
Sponsors:   KangLaiTe USA;   KangLaiTe USA
Recruiting - verified November 2011

Condition:   Smoldering Multiple Myeloma
Interventions:   Drug: Siltuximab;   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   Janssen Research & Development, LLC
Recruiting - verified February 2012

Conditions:   Head and Neck Neoplasms;   Lung Neoplasms;   Urinary Bladder Neoplasms;   Breast Neoplasms
Interventions:   Drug: Tetrahydrouridine (THU);   Drug: [F-18]-5-FLUORO-2'-DEOXYCYTIDINE
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified October 2011

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: mibefradil dihydrochloride;   Drug: temozolomide;   Other: 3'-deoxy-3'-[18F]fluorothymidine;   Other: pharmacological study
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI);   Tau Therapeutics LLC
Recruiting - verified April 2012

Condition:   HPV-related Head and Neck Cancer
Intervention:   Biological: pNGVL-4a-CRT/E7 (detox) DNA vaccine
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   National Institute of Dental and Craniofacial Research (NIDCR);   Milton J. Dance, Jr. Head and Neck Center at Greater Baltimore Medical Center;   Ichor Medical System Incorporated
Recruiting - verified April 2012

Condition:   Colorectal Cancer
Interventions:   Drug: Tivozanib;   Drug: Bevacizumab;   Drug: mFOLFOX6
Sponsors:   Astellas Pharma Inc;   Astellas Pharma Inc;   AVEO Pharmaceuticals, Inc.
Recruiting - verified March 2012

Conditions:   Chronic Myelogous Leukemia/Other Leukemia;   Acute Leukemias;   MDS/MPS;   Multiple Myeloma;   Non-Hodgkin Lymphoma
Intervention:   Drug: Access to unlicensed cord blood units
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified September 2011

Condition:   HER2 Negative Breast Cancer
Interventions:   Biological: NeuVax vaccine;   Biological: Leukine (sargramostim, GM-CSF) and water for injection
Sponsors:   Galena Biopharma, Inc.;   Galena Biopharma, Inc.
Recruiting - verified May 2012

Conditions:   Acute Lymphoblastic Leukemia;   Precursor B-Cell Lymphoblastic Leukemia;   Precursor T-Cell Lymphoblastic Leukemia
Interventions:   Drug: Decitabine;   Drug: Vorinostat;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Mitoxantrone;   Drug: Pegaspargase;   Drug: Methotrexate
Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   Therapeutic Advances in Childhood Leukemia Consortium
Recruiting - verified March 2012

Condition:   Breast Cancer
Interventions:   Device: MammaPrint;   Device: BluePrint;   Device: TargetPrint;   Device: TheraPrint
Sponsors:   Agendia;   Agendia
Recruiting - verified April 2012

Conditions:   Glioblastoma;   Small Cell Glioblastoma;   Giant Cell Glioblastoma;   Gliosarcoma;   Glioblastoma With Oligodendroglial Component
Interventions:   Drug: Rindopepimut (CDX-110) with GM-CSF;   Drug: Temozolomide;   Drug: KLH
Sponsors:   Celldex Therapeutics;   Celldex Therapeutics
Recruiting - verified May 2012

Condition:   Multiple Myeloma
Intervention:   Drug: PCI-32765
Sponsors:   Pharmacyclics;   Pharmacyclics
Recruiting - verified May 2012

Condition:   Lung Cancer - Non Small Cell
Interventions:   Biological: Ipilimumab;   Biological: Pemetrexed
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Not yet recruiting - verified February 2012

Condition:   Pancreatic Cancer
Interventions:   Drug: GS-6624;   Drug: GS-6624;   Drug: Placebo;   Drug: Gemcitabine;   Drug: Gemcitabine;   Drug: Gemcitabine;   Drug: Gemcitabine;   Drug: GS-6624
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified March 2012

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions:   Drug: paclitaxel;   Drug: pazopanib hydrochloride;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Colorectal Cancer
Interventions:   Drug: GS-6624;   Drug: FOLFIRI;   Drug: GS-6624;   Drug: FOLFIRI;   Drug: GS-6624;   Drug: FOLFIRI;   Drug: Placebo;   Drug: FOLFIRI
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified March 2012

Conditions:   Sarcoma;   Stomach Neoplasms;   Neoplasms
Interventions:   Drug: Pazopanib;   Drug: ARQ 197
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified October 2011

Condition:   Follicular Lymphoma
Interventions:   Drug: Rituximab;   Drug: Lenalidomide;   Drug: Rituximab-CHOP;   Drug: Rituximab-CVP;   Drug: Rituximab-Bendamustine
Sponsors:   Celgene Corporation;   Celgene Corporation;   Groupe d'Etude des Lymphomes de l'Adulte - Recherche Clinique
Recruiting - verified April 2012

Condition:   Prostate Cancer
Intervention:   Drug: Lovastatin
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified April 2012

Conditions:   Glioblastoma Multiforme;   Gliosarcoma;   Anaplastic Astrocyloma;   Oligoastrocytoma;   Malignant Glioma
Intervention:   Drug: AZD7451
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified September 2011

Condition:   Multiple Myeloma
Interventions:   Biological: Elotuzumab;   Drug: Bortezomib;   Drug: Dexamethasone;   Drug: Dexamethasone;   Drug: Dexamethasone;   Drug: Dexamethasone
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Abbott Biotherapeutics Corp.
Recruiting - verified February 2012

Conditions:   Hodgkin Disease;   Hodgkin Lymphoma
Interventions:   Drug: Filgrastim;   Drug: Plerixafor;   Drug: Yttrium-Daclizumab (CHX-A Daclizumab);   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan;   Drug: Ca(2+)-DTPA
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified September 2011

Condition:   Glioblastoma Multiforme
Interventions:   Radiation: Radiation;   Drug: Chemotherapy
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified April 2012

Condition:   Glioblastoma Multiforme
Interventions:   Radiation: Low Dose Fractionated Radiation Therapy (LDFRT);   Drug: Temozolomide
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting - verified April 2012

Condition:   Pancreatic Cancer
Interventions:   Drug: Gemcitabine;   Drug: Taxotere;   Drug: Xeloda;   Drug: Cisplatin
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified December 2011

Condition:   Lymphoma
Interventions:   Drug: alisertib;   Genetic: fluorescence in situ hybridization;   Genetic: microarray analysis;   Genetic: mutation analysis;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Pituitary Neoplasm
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified August 2011

Condition:   Multiple Myeloma
Interventions:   Drug: masitinib 6 mg/kg/day;   Drug: placebo
Sponsors:   AB Science;   AB Science
Recruiting - verified November 2011

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: onartuzumab [MetMAb];   Drug: erlotinib [Tarceva];   Drug: Placebo
Sponsors:   Genentech;   Genentech;   Hoffmann-La Roche
Recruiting - verified January 2012

Conditions:   Renal Cell Carcinoma;   Clear-cell Metastatic Renal Cell Carcinoma
Interventions:   Biological: BMS-936558;   Drug: Sunitinib;   Drug: Pazopanib
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Ono Pharmaceutical Company, Ltd.
Recruiting - verified March 2012

Condition:   Leukemia, Pediatric
Intervention:   Drug: Dasatinib
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Children's Oncology Group;   EsPhALL - European Intergroup Study on Post Induction Treatment of Philadelphia Positive Acute Lymphoblastic Leukaemia with Imatinib
Recruiting - verified April 2012

Condition:   Endometrial Carcinoma
Intervention:   Drug: GDC-0980
Sponsors:   Genentech;   Genentech
Recruiting - verified October 2011

Condition:   HIV Infection
Intervention:  
Sponsors:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   National Institute on Drug Abuse (NIDA);   National Institute of Mental Health (NIMH)
Recruiting - verified November 2011

Conditions:   Metastatic Melanoma;   Skin Cancer
Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Young TIL
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified September 2011

Conditions:   Malignant Glioma;   Glioblastoma;   Brain Cancer
Interventions:   Genetic: Anti-EGFRvIII CAR (PG13-139-CD8-CD28BBZ (F10) transduced PBL;   Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   Acute Myelogenous Leukemia (AML)
Interventions:   Drug: MK-8242;   Drug: MK-8242;   Drug: cytarabine
Sponsors:   Schering-Plough;   Schering-Plough
Recruiting - verified May 2012

Conditions:   Esophageal Cancer;   Stomach Cancer;   Pancreatic Cancer
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Breast Cancer;   Ovarian Cancer
Interventions:   Drug: AZ2281;   Drug: Carboplatin
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified July 2011

Condition:   Breast Cancer
Interventions:   Radiation: 111 Indium CHX-A DTPA-Trastuzumab;   Drug: 111Indium Trastuzumab
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Sarcoma;   Wilm's Tumor;   Lymphoma;   Neuroblastoma
Intervention:   Drug: Ipilimumab(anti-CTLA-4 antibody)
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Brain Metastasis;   Cancer
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified November 2011

Conditions:   Refractory Solid Tumors;   Refractory Leukemias
Intervention:   Drug: BAY 43-9006
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified December 2011

Condition:   Solid Tumors
Interventions:   Drug: Bevacizumab;   Drug: Dasatinib
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Radiation Therapy
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified December 2011

Conditions:   HIV Infections;   Central Nervous System Neoplasms;   Neurofibromatosis 1
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified September 2011

Conditions:   Mycosis Fungoides;   Cutaneous T-Cell Lymphoma;   Neoplasms
Intervention:   Drug: Romidepsin (FR901228)
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified August 2011

Condition:   Myelodysplastic Syndrome (MDS)
Intervention:   Drug: ezatiostat hydrochloride (Telintra®)
Sponsors:   Telik;   Telik
Recruiting - verified October 2011

Conditions:   Li-Fraumeni Syndrome;   Neoplasms;   Tp53 Mutations
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified August 2011

Condition:   Recurrent Gliomas
Interventions:   Drug: Enzastaurin (LY317615);   Drug: Carboplatin
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Prostate Cancer;   Breast Cancer;   Lung Cancer;   Ovarian Cancer;   Lymphoma
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Not yet recruiting - verified March 2012

Conditions:   Cancer;   Neoplasm Metastasis;   Radiation Oncology;   Neoplasm;   Metastasis
Interventions:   Procedure: Radiation Therapy;   Drug: ECI301
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified August 2011

Conditions:   Malignant Struma Ovarii;   Papillary Thyroid Cancer;   Hurthle Cell Thyroid Cancer;   Follicular Thyroid Cancer;   Tall Cell Variant Thyroid Cancer
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified August 2011

Conditions:   Ureteral Neoplasms;   Urinary Bladder Neoplasms;   Urethral Neoplasms
Interventions:   Drug: Lenalidomide;   Drug: Cisplatin;   Drug: Gemcitabine
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified January 2012

Conditions:   Carcinoma, Non-Small Cell Lung;   Adenocarcinoma;   Carcinoma, Squamous Cell;   Carcinoma, Large Cell
Interventions:   Drug: PF-00299804;   Drug: PF-02341066
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified August 2011

Conditions:   Stress;   Family Caregivers
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institutes of Health Clinical Center (CC)
Recruiting - verified September 2011

Condition:   Mesothelioma
Interventions:   Drug: SS1P;   Drug: Pemetrexed;   Drug: Cisplatin
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Breast Neoplasms
Intervention:   Behavioral: Decision control preference scale
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified October 2011

Condition:   Prostate Cancer
Interventions:   Biological: AdV-tk + valacyclovir;   Biological: Placebo + valacyclovir
Sponsors:   Advantagene, Inc.;   Advantagene, Inc.
Recruiting - verified May 2012

Condition:   Transverse Myelitis
Interventions:   Drug: Dalfampridine;   Drug: Placebo controlled
Sponsors:   Johns Hopkins University;   Johns Hopkins University;   Acorda Therapeutics
Not yet recruiting - verified March 2012

Condition:   Extensive Stage Small Cell Lung Carcinoma
Interventions:   Drug: LY2510924;   Drug: Carboplatin;   Drug: Etoposide
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified February 2012

Conditions:   Colorectal Cancer With Hepatic Metastases;   Pancreas Cancer With Hepatic Metastase;   Gastric Cancer With Hepatic Metastase;   Breast Cancer With Hepatic Metastase;   Ovarian Cancer With Hepatic Metastase
Intervention:   Drug: TKM-080301
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: BMS-936558 (Anti-PD1);   Drug: BMS-936558 (Anti-PD1);   Drug: BMS-936558 (Anti-PD1);   Drug: Gemcitabine;   Drug: Cisplatin;   Drug: Pemetrexed;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Ono Pharma
Recruiting - verified February 2012

Conditions:   Castleman Disease;   Castleman's Disease;   Giant Lymph Node Hyperplasia
Interventions:   Drug: Zidovudine;   Drug: Tocilizumab;   Drug: Valganciclovir
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified July 2011

Condition:   Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
Interventions:   Drug: MEDI-573;   Drug: Aromatase Inhibitor
Sponsors:   MedImmune LLC;   MedImmune LLC
Recruiting - verified May 2012

Condition:   Acute Lymphoblastic Leukemia
Intervention:  
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified September 2011

Condition:   Multiple Myeloma
Intervention:   Drug: DFRF4539A
Sponsors:   Genentech;   Genentech
Recruiting - verified April 2012

Condition:   Breast Cancer
Interventions:   Biological: Ramucirumab (IMC-1121B);   Drug: Eribulin
Sponsors:   ImClone LLC;   ImClone LLC
Recruiting - verified May 2012

Condition:   Melanoma
Interventions:   Biological: melanoma GVAX;   Drug: Cyclophosphamide
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   The John P. Hussman Foundation
Recruiting - verified September 2011

Condition:   Oncology
Intervention:   Drug: BAY94-9343
Sponsors:   Bayer;   Bayer
Recruiting - verified May 2012

Condition:   Urothelial Carcinoma
Interventions:   Drug: Cabazitaxel;   Drug: Neulasta;   Procedure: CT Scan;   Biological: Blood Draw
Sponsors:   Thomas Jefferson University;   Thomas Jefferson University;   Sanofi-Aventis
Recruiting - verified April 2012

Conditions:   Solid Tumors;   Advanced Thyroid Cancer
Intervention:   Drug: Combination of pazopanib and GSK1120212
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   National Comprehensive Cancer Network;   GlaxoSmithKline
Recruiting - verified May 2012

Condition:   Sturge-Weber Syndrome
Intervention:  
Sponsors:   Hugo W. Moser Research Institute at Kennedy Krieger, Inc.;   Hugo W. Moser Research Institute at Kennedy Krieger, Inc.;   National Institutes of Health (NIH);   University of California, San Francisco;   National Institute of Neurological Disorders and Stroke (NINDS);   Duke University;   Children's Hospital of Michigan;   Baylor College of Medicine;   Texas Children's Hospital;   Wills Eye;   Nationwide Children's Hospital
Recruiting - verified February 2012

Condition:   Breast Cancer
Interventions:   Drug: trastuzumab emtansine;   Drug: anti-cancer therapy
Sponsors:   Genentech;   Genentech
Recruiting - verified March 2012

Conditions:   Epithelial Neoplasms, Malignant;   Epithelial Tumors, Malignant;   Malignant Mesenchymal Tumor
Intervention:   Drug: NHS-IL-12
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified July 2011

Condition:   Prostate Cancer
Intervention:   Drug: Leuprolide acetate 22.5 mg depot, GP-Pharm SA
Sponsors:   GP-Pharm;   GP-Pharm
Recruiting - verified March 2012

Condition:   Metastatic Breast Cancer
Interventions:   Drug: LY2523355;   Drug: Ixabepilone;   Drug: pegfilgrastim;   Drug: filgrastim
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified May 2012

Conditions:   Myelofibrosis;   Gaucher Disease;   Pulmonary Fibrosis;   Hermansky-Pudlak Syndrome (HPS);   Cancer
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Human Genome Research Institute (NHGRI)
Recruiting - verified June 2011

Condition:   Pancreatic Cancer
Interventions:   Drug: GVAX Pancreas, Cyclophosphamide and CRS-207;   Drug: GVAX Pancreas and Cyclophosphamide
Sponsors:   Aduro BioTech, Inc.;   Aduro BioTech, Inc.;   Johns Hopkins University
Recruiting - verified May 2012

Conditions:   Carcinoma, Pancreatic Ductal;   Mesothelioma;   Ovarian Neoplasms;   Carcinoma, Non-Small-Cell Lung
Intervention:   Drug: Amatuximab (MORab-009)
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Leukemia
Interventions:   Drug: bortezomib;   Drug: decitabine
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Glioblastoma;   Brain Neoplasm
Intervention:   Procedure: Craniotomy
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified April 2012

Conditions:   Prostatic Neoplasm;   Prostate Cancer;   Prostatic Adenocarcinoma
Interventions:   Biological: sipuleucel-T;   Drug: leuprolide acetate
Sponsors:   Dendreon;   Dendreon
Recruiting - verified May 2012

Condition:   Myelodysplastic Syndrome (MDS)
Intervention:   Drug: ezatiostat hydrochloride (Telintra®)
Sponsors:   Telik;   Telik
Recruiting - verified August 2011

Condition:   Carotid Artery Plaque
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified July 2011

Condition:   Bladder Cancer
Interventions:   Drug: Apaziquone;   Drug: Placebo
Sponsors:   Spectrum Pharmaceuticals, Inc;   Spectrum Pharmaceuticals, Inc;   Allergan
Recruiting - verified April 2012

Conditions:   Lymphoma, Diffuse Large-Cell B-cell;   Diffuse, Large B-cell Lymphoma;   Lymphoma, Diffuse Large-Cell;   Large-Cell Lymphoma, Diffuse
Interventions:   Drug: MLN4924;   Drug: Etoposide;   Drug: Prednisone;   Drug: Vincristine;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Rituximab;   Drug: Filgrastim
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Not yet recruiting - verified April 2012

Conditions:   Leukemia;   Lymphoma;   HIV
Interventions:   Drug: Fludarabine and Busulfan (Flu/Bu);   Drug: Fludarabine and Melphalan (Flu/Mel);   Drug: Busulfan and Fludarabine (Bu/Flu);   Drug: Cyclophosphamide and Total Body Irradiation (Cy/TBI);   Drug: Fludarabine;   Drug: Busulfan, Fludarabine, Cyclophosphamide
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network
Recruiting - verified March 2012

Condition:   Lymphoma
Interventions:   Biological: rituximab;   Drug: bendamustine hydrochloride;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: vincristine sulfate
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Lymphoblastic Leukemia, Acute, Childhood;   Myelogenous Leukemia, Acute, Childhood
Interventions:   Drug: AC220;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Methotrexate
Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   Therapeutic Advances in Childhood Leukemia Consortium;   Ambit Biosciences Corporation
Recruiting - verified September 2011

Condition:   Metastatic Breast Cancer
Interventions:   Drug: eribulin mesylate;   Drug: eribulin mesylate;   Drug: eribulin mesylate, trastuzumab
Sponsors:   Sarah Cannon Research Institute;   Sarah Cannon Research Institute;   Eisai Inc.
Recruiting - verified March 2012

Conditions:   Cognitive/Functional Effects;   Leukemia;   Neurotoxicity;   Pain;   Therapy-related Toxicity
Interventions:   Drug: clofarabine;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: hydrocortisone sodium succinate;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: selective external radiation therapy
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Colorectal Neoplasms;   Digestive System Diseases;   Colonic Diseases;   Colorectal Cancer
Intervention:  
Sponsors:   Exact Sciences Corporation;   Exact Sciences Corporation
Recruiting - verified August 2011

Condition:   Multiple Myeloma
Interventions:   Drug: Carfilzomib;   Drug: Lenalidomide;   Drug: Dexamethasone
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI);   Celgene Corporation;   Onyx Therapeutics, Inc.
Recruiting - verified July 2011

Condition:   Acute Promyelocytic Leukemia
Intervention:   Drug: Tretinoin and Arsenic Trioxide
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Northwestern University;   New York Presbyterian Hospital;   University of Southern California;   Princess Margaret Hospital, Canada;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2012

Condition:   Resectable Pancreatic Adenocarcinoma
Interventions:   Drug: LDE-225;   Drug: Gemcitabine
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   Novartis
Recruiting - verified March 2012

Condition:   Glioblastoma
Interventions:   Drug: Cyclophosphamide;   Biological: IMA950 plus GM-CSF;   Biological: IMA950;   Drug: Imiquimod
Sponsors:   immatics Biotechnologies GmbH;   immatics Biotechnologies GmbH;   National Cancer Institute (NCI)
Recruiting - verified October 2011

Conditions:   Chemotherapeutic Agent Toxicity;   Cognitive/Functional Effects;   Lymphoma;   Neurotoxicity;   Radiation Toxicity
Interventions:   Biological: rituximab;   Drug: cytarabine;   Drug: methotrexate;   Drug: procarbazine hydrochloride;   Drug: vincristine sulfate;   Radiation: whole-brain radiation therapy
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Dexamethasone;   Drug: Dexamethasone;   Biological: Elotuzumab (BMS-901608; HuLuc63);   Drug: Lenalidomide;   Drug: Lenalidomide
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Abbott Biotherapeutics Corp.
Recruiting - verified October 2011

Condition:   Metastatic Non-Small Cell Lung Cancer
Interventions:   Drug: ARQ 197 plus erlotinib;   Drug: Pemetrexed, docetaxel or gemcitabine
Sponsors:   ArQule;   ArQule
Recruiting - verified January 2012

Condition:   Lung Cancer
Interventions:   Drug: carboplatin;   Drug: paclitaxel;   Drug: veliparib;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Beckman Research Institute;   National Cancer Institute (NCI)
Recruiting - verified June 2011

Condition:   Sarcoma, Alveolar Soft Part
Interventions:   Drug: Cediranib;   Drug: Sunitinib
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Cachexia;   Non-Small Cell Lung Cancer
Interventions:   Drug: Anamorelin HCl;   Drug: Placebo
Sponsors:   Helsinn Therapeutics (U.S.), Inc;   Helsinn Therapeutics (U.S.), Inc
Recruiting - verified May 2012

Conditions:   Arthralgia;   Breast Cancer;   Pain
Interventions:   Dietary Supplement: omega-3 fatty acid;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Leukemia, Myeloid, Acute
Interventions:   Drug: AC220;   Drug: daunorubicin;   Drug: cytarabine
Sponsors:   Astellas Pharma Inc;   Astellas Pharma Inc;   Ambit Biosciences Corporation
Recruiting - verified May 2012

Conditions:   Optic Glioma;   Pilocytic Astrocytoma;   Low Grade Glioma;   Fibriullary Astrocytoma
Intervention:   Drug: AZD6244
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   Acute Myeloid Leukemia
Intervention:  
Sponsors:   Center for International Blood and Marrow Transplant Research;   Center for International Blood and Marrow Transplant Research;   Resource for Clinical Investigations in Blood and Marrow Transplantation (RCI-BMT);   Pediatric Blood and Marrow Transplant Consortium
Recruiting - verified May 2012

Condition:   Advanced Solid Tumors
Intervention:   Drug: linifanib
Sponsors:   Abbott;   Abbott
Recruiting - verified May 2012

Condition:   Multiple Myeloma
Intervention:   Drug: MLN9708 + Lenalidomide + Dexamethasone
Sponsors:   Millennium Pharmaceuticals, Inc.;   Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012

Conditions:   Prostate Cancer;   Prostatic Neoplasms
Intervention:   Device: Visualase Thermal Therapy System
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Hepatocellular Carcinoma;   Hepatocellular Cancer;   Carcinoma, Hepatocellular
Intervention:   Drug: TRC105
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Esophageal Cancer
Interventions:   Drug: Paclitaxel with Cisplatin;   Drug: Arm B
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified June 2011

Conditions:   Metastatic Melanoma;   Skin Cancer
Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Aldesleukin;   Biological: Tumor Infiltrating Lymphocytes
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Multiple Myeloma
Intervention:   Drug: Tadalafil, Cialis
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified January 2012

Condition:   Prostate Cancer
Interventions:   Radiation: radiation therapy;   Radiation: selective external radiation therapy
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Metastatic Melanoma;   Skin Cancer
Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Tumor Infiltrating Lymphocytes;   Drug: IL-15
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Leukemia
Interventions:   Drug: asparaginase;   Drug: bortezomib;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: mitoxantrone hydrochloride;   Drug: sorafenib tosylate
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Cancer
Interventions:   Drug: carboplatin;   Drug: paclitaxel;   Drug: veliparib;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   University of Pittsburgh;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Conditions:   Crohn's Disease;   IBD;   Colitis;   Inflammatory Bowel Disease
Interventions:   Drug: Group 2 ustekinumab 130 mg;   Drug: Group 3: ustekinumab approximately 6 mg/kg;   Drug: Group 1: Placebo
Sponsors:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified April 2012

Conditions:   Pediatric Leukemia;   Other Pediatric Cancers
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Coronary Artery Disease;   Proteus Syndrome;   Coffin - Sins Syndrome;   Familial Isolated Hyperparathyroidism;   Dubouitz Syndrome
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Human Genome Research Institute (NHGRI)
Recruiting - verified March 2012

Conditions:   Bacterial Infection;   Leukemia;   Musculoskeletal Complications;   Neutropenia
Interventions:   Drug: levofloxacin;   Procedure: standard follow-up care
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Endometrial Cancer
Interventions:   Drug: Carboplatin/Paclitaxel;   Drug: Trastuzumab
Sponsors:   Yale University;   Yale University;   Genentech
Recruiting - verified January 2012

Condition:   Hematologic Neoplasms
Intervention:  
Sponsors:   Center for International Blood and Marrow Transplant Research;   Center for International Blood and Marrow Transplant Research;   National Marrow Donor Program
Recruiting - verified June 2011

Condition:   Multiple Myeloma
Interventions:   Drug: Group A: Carfilzomib & Non-IMiD Regimen;   Drug: Group B: Carfilzomib & IMiD containing regimen.
Sponsors:   Oncotherapeutics;   Oncotherapeutics;   Onyx Pharmaceuticals
Recruiting - verified February 2012

Conditions:   Neurofibromatosis 1;   Neurofibromatosis Type 1;   NF 1;   Neurofibroma, Plexiform
Intervention:   Drug: AZD6244 hyd sulfate
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   Breast Cancer
Interventions:   Drug: pertuzumab;   Drug: placebo;   Drug: trastuzumab [Herceptin];   Drug: Chemotherapy
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche;   Breast International Group;   Genentech
Recruiting - verified February 2012

Condition:   Lung Cancer, Non-Small Cell
Interventions:   Drug: GSK1120212;   Drug: docetaxel
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified May 2012

Condition:   Mesothelioma
Interventions:   Drug: Pentostatin;   Drug: Cyclophosphamide;   Drug: SS1P
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Acute Myelogenous Leukemia
Intervention:   Drug: R115777
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   H. Lee Moffitt Cancer Center and Research Institute;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Urethral Neoplasms;   Neoplasms, Urethral;   Ureter Cancer;   Cancer of the Urethra;   Urethral Cancer
Interventions:   Drug: Gemcitabine;   Drug: Carboplatin;   Drug: Lenalidomide
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   Renal Cell Carcinoma
Interventions:   Drug: BMS-936558 (Anti-PD-1);   Drug: BMS-936558 (Anti-PD-1);   Drug: BMS-936558 (Anti-PD-1)
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Ono Pharma
Recruiting - verified February 2012

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: bevacizumab [Avastin];   Drug: Standard of care treatment
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified May 2012

Conditions:   Hematological Malignancies;   Certain Lysosomal Storage and Peroxisomal Enzyme Deficiency Disorders;   Hurler Syndrome (MPS I);   Krabbe Disease (Globoid Leukodystrophy);   X-linked Adrenoleukodystrophy;   Primary Immunodeficiency Diseases;   Bone Marrow Failure;   Beta-thalassemia
Intervention:   Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Sponsors:   Center for International Blood and Marrow Transplant Research;   Center for International Blood and Marrow Transplant Research;   National Marrow Donor Program
Recruiting - verified April 2012

Conditions:   Hepatitis;   HIV;   Liver Cancer
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institutes of Health Clinical Center (CC);   Washington DC Veterans Affairs Medical Center
Recruiting - verified February 2012

Condition:   Breast Cancer
Interventions:   Drug: azacitidine;   Drug: entinostat;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Mayo Clinic;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Breast Cancer
Interventions:   Radiation: 3-dimensional conformal radiation therapy;   Radiation: accelerated radiation therapy;   Radiation: hypofractionated radiation therapy;   Radiation: intensity-modulated radiation therapy;   Radiation: whole breast irradiation
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Neuroblastoma
Intervention:   Device: Guided Therapy
Sponsors:   Van Andel Research Institute;   Giselle Sholler
Recruiting - verified April 2012

Condition:   Adrenal Gland Neoplasms
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   Renal Cell Carcinoma
Interventions:   Biological: BMS-936558;   Biological: BMS-936558;   Biological: BMS-936558
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Ono Pharma
Recruiting - verified February 2012

Conditions:   Non-Small Cell Lung Cancer (Stage III);   Colon Cancer (Stage II & III);   Rectal Cancer (Stage III)
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Lenalidomide;   Biological: Allogeneic Myeloma Vaccine
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   Celgene Corporation
Recruiting - verified March 2012

Conditions:   Cancer;   Hematologic Malignancies;   Multiple Myeloma;   Oncology;   Bone Metastases;   Multiple Myeloma Bone Lesions
Interventions:   Drug: Denosumab;   Drug: Zoledronic acid
Sponsors:   Amgen;   Amgen;   Daiichi Sankyo Inc.
Recruiting - verified May 2012

Conditions:   Systemic Myeloma;   Multifocal Myeloma
Interventions:   Genetic: Autologous Genetically modified T cells;   Biological: Prevnar -13
Sponsors:   Abramson Cancer Center of the University of Pennsylvania;   Abramson Cancer Center of the University of Pennsylvania;   University of Maryland Greenebaum Cancer Center;   Adaptimmune Ltd.
Recruiting - verified January 2012

Condition:   Leukemia
Interventions:   Drug: alvocidib;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: idarubicin;   Drug: mitoxantrone hydrochloride
Sponsors:   National Cancer Institute (NCI);   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia
Interventions:   Drug: entinostat;   Drug: imatinib mesylate;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Genetic: western blotting;   Other: immunohistochemistry staining method;   Other: flow cytometry;   Genetic: polymerase chain reaction;   Other: high performance liquid chromatography;   Other: mass spectrometry
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   Acute Myelogenous Leukemia
Interventions:   Drug: FLAM;   Drug: 7&3
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified January 2012

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: PLX3397;   Drug: PLX3397
Sponsors:   Plexxikon;   Plexxikon
Recruiting - verified May 2012

Conditions:   DDD;   Deformity;   Tumor;   Fracture
Intervention:  
Sponsors:   Biomet, Inc.;   Biomet, Inc.
Recruiting - verified February 2012

Conditions:   Sarcoma;   Melanoma;   Epithelial Malignancies;   Pleural Malignancy
Interventions:   Biological: Epigenetically Modified Autologous Tumor;   Drug: Cyclophosphamide;   Drug: Celecoxib
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified December 2011

Conditions:   Breast Cancer;   Colon Cancer;   Bladder Cancer
Interventions:   Drug: Glycosylated Recombinant Human Interleukin-7;   Biological: Diphtheria-Tetanus Vaccine;   Biological: Polio Vaccine;   Biological: Pneumaococcal Vaccine;   Biological: Hepatitis A Vaccine;   Biological: Hepatitis B Vaccine;   Biological: Influenza Vaccine;   Biological: PhiX 174
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   Sturge-Weber Syndrome
Intervention:  
Sponsors:   Hugo W. Moser Research Institute at Kennedy Krieger, Inc.;   Hugo W. Moser Research Institute at Kennedy Krieger, Inc.;   National Institutes of Health (NIH);   University of California, San Francisco;   National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified February 2012

Condition:   Advanced Liposarcoma or Leiomyosarcoma
Interventions:   Drug: Trabectedin;   Drug: Dacarbazine
Sponsors:   Janssen Research & Development, LLC;   Janssen Research & Development, LLC;   Pharma Mar, S.A.U.
Recruiting - verified May 2012

Condition:   Synovial Sarcoma
Intervention:   Other: NY-ESO-1 T Cells
Sponsors:   University of Pennsylvania;   University of Pennsylvania;   Adaptimmune Ltd.;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   Lung Cancer
Interventions:   Procedure: therapeutic conventional surgery;   Radiation: iodine I 125;   Radiation: stereotactic body radiation therapy
Sponsors:   National Cancer Institute (NCI);   American College of Surgeons;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Hodgkin's Lymphoma;   Leukemia;   Myelodysplastic Syndrome(MDS);   Multiple Myeloma;   Non Hodgkin's Lymphoma
Intervention:   Procedure: Bone Marrow Transplant
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified January 2012

Conditions:   Neoplasm Metastases;   Melanoma;   Colorectal Neoplasms
Interventions:   Drug: Irinotecan;   Procedure: Chemoembolization;   Device: Drug-Eluting Beads;   Procedure: Biopsy
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institutes of Health Clinical Center (CC)
Recruiting - verified January 2012

Conditions:   Extra-adrenal Paraganglioma;   Paraganglioma;   Pheochromocytoma
Interventions:   Drug: pazopanib hydrochloride;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Mayo Clinic;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Chemotherapy-Induced Nausea and Vomiting
Interventions:   Drug: Netupitant and Palonosetron;   Drug: Palonosetron
Sponsors:   Helsinn Healthcare SA;   Helsinn Healthcare SA;   Parexel
Recruiting - verified December 2011

Conditions:   Acute Lymphocytic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome RAEB 1
Interventions:   Drug: Lupron;   Drug: 18F FLT;   Drug: Cyclophosphamide;   Drug: Methotrexate;   Drug: Tacrolimus;   Drug: Total Body Irradiation
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified December 2011

Condition:   Colorectal Neoplasms
Interventions:   Drug: MK-2206;   Drug: AZD6244
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified December 2011

Condition:   Hepatocellular Carcinoma
Interventions:   Device: HepaSphere/QuadraSphere Microspheres;   Procedure: PVA, lipiodol, doxorubicin
Sponsors:   Merit Medical Systems, Inc.;   Merit Medical Systems, Inc.
Recruiting - verified January 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Dexamethasone;   Drug: Dexamethasone;   Drug: Dexamethasone;   Biological: Elotuzumab (BMS-901608; HuLuc63);   Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Abbott Biotherapeutics Corp.
Recruiting - verified October 2011

Conditions:   Non-Small Cell Lung Cancer;   Cancer
Intervention:   Drug: GSK2118436
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified May 2012

Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer
Interventions:   Drug: FOLFOX regimen;   Drug: carboplatin;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Drug: paclitaxel
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Neuroblastoma
Interventions:   Biological: hu14.18-IL2 fusion protein;   Biological: sargramostim;   Drug: isotretinoin;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Anal Cancer
Interventions:   Drug: Tempol;   Drug: 5-Fluorouracil;   Drug: Mitomycin-C;   Procedure: Radiation Therapy
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified November 2011

Condition:   Prostate Cancer Metastatic
Interventions:   Biological: PROSTVAC-V/F-TRICOM + GM-CSF;   Biological: PROSTVAC-V/F-TRICOM + GM-CSF placebo;   Biological: Placebo
Sponsors:   BN ImmunoTherapeutics;   BN ImmunoTherapeutics
Recruiting - verified January 2012

Condition:   Basal Cell Carcinoma
Intervention:   Drug: LDE225
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Condition:   Carcinoid
Intervention:   Drug: YF476
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified October 2011

Conditions:   Lymphoblastic Leukemia, Acute, Childhood;   Myelogenous Leukemia, Acute, Childhood;   Hodgkin's Disease;   Non-Hodgkin's Lymphoma
Interventions:   Drug: Panobinostat;   Drug: Cytarabine;   Drug: Panobinostat
Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   Therapeutic Advances in Childhood Leukemia Consortium;   Novartis
Recruiting - verified November 2011

Conditions:   Metastatic Melanoma;   Skin Cancer
Interventions:   Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Young Tumor Infiltrating Lymphocytes;   Procedure: 1200 Gy Irradiation
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified November 2011

Condition:   Gastrointestinal Stromal Tumor (GIST)
Intervention:   Biological: IMC-3G3
Sponsors:   ImClone LLC;   ImClone LLC
Recruiting - verified March 2012

Condition:   Prostate Cancer
Intervention:   Drug: Muscadine Plus Grape Skin Extract
Sponsors:   Johns Hopkins University;   Johns Hopkins University;   Howard University;   Department of Defense: Prostate Cancer Clinical Trial Consortium
Recruiting - verified March 2011

Conditions:   Diffuse Large B-cell Lymphoma;   de Novo DLBCL;   DLBCL Transformed From Indolent Lymphoma;   Follicular Grade 3 Lymphoma
Interventions:   Drug: Pixantrone + Rituximab;   Drug: Gemcitabine + Rituximab
Sponsors:   Cell Therapeutics;   Cell Therapeutics
Recruiting - verified May 2012

Conditions:   Gastrointestinal Neoplasms;   Cancer of Gastrointestinal Tract;   Cancer of the Gastrointestinal Tract;   Gastrointestinal Cancer;   Neoplasms, Gastrointestinal
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified December 2011

Conditions:   Sarcoma;   Melanoma;   Epithelial Malignancies;   Pleural Malignancies
Intervention:   Biological: Allogenic Tumor Cell Vaccine (K562)
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified September 2011

Condition:   Thyroid Cancer
Interventions:   Drug: lenvatinib 24 mg administered orally, once a day;   Drug: Placebo 24mg administered orally, once a day
Sponsors:   Eisai Inc.;   Eisai Inc.
Recruiting - verified April 2012

Conditions:   Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Malignant Glioma;   Brainstem Glioma
Intervention:   Drug: AZD8055
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified September 2011

Condition:   Prostate Cancer
Intervention:   Other: Questionnaire
Sponsors:   Dana-Farber Cancer Institute;   Beth Israel Deaconess Medical Center;   Brigham and Women's Hospital;   The Cleveland Clinic;   Johns Hopkins University;   University of California, San Francisco;   University of Michigan;   Vanderbilt University;   Washington University School of Medicine
Recruiting - verified May 2012

Conditions:   Oropharyngeal Cancer;   Human Papillomavirus
Intervention:  
Sponsors:   Johns Hopkins Bloomberg School of Public Health;   Johns Hopkins Bloomberg School of Public Health;   Mount Sinai School of Medicine;   Oregon Health and Science University;   Dana-Farber Cancer Institute;   Johns Hopkins Hospital (JHH)
Recruiting - verified May 2012

Conditions:   Prostate Cancer;   Prostatic Neoplasm
Intervention:   Drug: abiraterone acetate in combination with prednisone
Sponsors:   Janssen Biotech, Inc.;   Janssen Biotech, Inc.
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Drug: Cabazitaxel (XRP6258);   Drug: Prednisone
Sponsors:   Sanofi-Aventis;   Sanofi-Aventis
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Drug: Cabazitaxel (XRP6258);   Drug: Docetaxel (XRP6976);   Drug: Prednisone
Sponsors:   Sanofi-Aventis;   Sanofi-Aventis
Recruiting - verified April 2012

Conditions:   Relapsed/Refractory AML;   Relapsed/Refractory ALL;   Secondary AML/MDS;   Acute Leukemia of Ambiguous Lineage;   AML;   ALL
Intervention:   Drug: Plerixafor Dose Escalation
Sponsors:   Emory University;   Emory University;   Children's Healthcare of Atlanta;   Pediatric Oncology Experimental Therapeutics Investigation Consortium
Recruiting - verified January 2012

Conditions:   Advanced Prostate Cancer;   Prostatic Neoplasms
Intervention:   Biological: sipuleucel-T
Sponsors:   Dendreon;   Dendreon
Recruiting - verified March 2012

Conditions:   Ovarian;   Primary Peritoneal;   Serous Carcinoma;   Triple-Negative Breast;   Fallopian Tube
Interventions:   Drug: ABT-888 with Cyclophospharmide;   Drug: Cyclophosphamide
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified November 2011

Conditions:   Carcinoma, Non-Small-Cell Lung;   Carcinoma, Small Cell Lung;   Carcinoma, Thymic
Interventions:   Drug: AZD;   Drug: MK-2206;   Drug: Lapatinib;   Drug: Erlotinib;   Drug: Sunitinib;   Procedure: Molecular Profiling
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified November 2011

Conditions:   Hepatoma;   Liver Neoplasms;   Adenoma, Liver Cell;   Carcinoma, Hepatocellular
Interventions:   Drug: TRC 105;   Drug: Sorafenib
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified December 2011

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions:   Biological: bevacizumab;   Drug: fosbretabulin tromethamine
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Adrenal Hyperplasia;   Polycystic Ovarian Syndrome;   Oligomenorrhea;   Obesity;   Hyperandrogenism
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified January 2012

Condition:   Conventional Chondrosarcoma
Interventions:   Drug: IPI-926;   Drug: Placebo Arm
Sponsors:   Infinity Pharmaceuticals, Inc.;   Infinity Pharmaceuticals, Inc.
Recruiting - verified May 2012

Conditions:   Head and Neck Cancer;   Precancerous Condition
Interventions:   Biological: cetuximab;   Drug: cisplatin
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Fungal Infection;   Leukemia;   Neutropenia
Interventions:   Drug: caspofungin acetate;   Drug: fluconazole
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Pancreatic Cancer
Interventions:   Biological: ganitumab;   Drug: capecitabine;   Drug: gemcitabine hydrochloride;   Radiation: 3-dimensional conformal radiation therapy
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Cervical Intraepithelial Neoplasia
Interventions:   Biological: VGX 3100;   Biological: Placebo
Sponsors:   Inovio Pharmaceuticals;   Inovio Pharmaceuticals
Recruiting - verified May 2012

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: Entinostat;   Drug: 5-azacitidine
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified April 2012

Condition:   Prostate Cancer
Intervention:   Drug: Ferumoxytol
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified August 2011

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: Sapacitabine and decitabine;   Drug: Decitabine
Sponsors:   Cyclacel Pharmaceuticals, Inc.;   Cyclacel Pharmaceuticals, Inc.
Recruiting - verified November 2011

Condition:   Gastrointestinal Stromal Tumor (GIST)
Intervention:   Drug: AT13387 and Imatinib
Sponsors:   Astex Pharmaceuticals;   Astex Pharmaceuticals
Recruiting - verified March 2012

Conditions:   Histologically or Cytologically Confirmed Pancreatic Ca;   Unresectable or Borderline Resectable Pancreatic Ca
Interventions:   Drug: Gemcitabine;   Procedure: Intra Arterial Catheterization and Embolization;   Device: Indwelling Intraarterial Catheter
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified December 2011

Conditions:   Solid Tumors;   Relapsed/Refractory Sarcomas
Intervention:   Drug: Vorinostat and Etoposide
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Merck;   Phoenix Children's Hospital;   Penn State Children's Hospital;   Johns Hopkins University;   Sidney Kimmel Comprehensive Cancer Center;   Children's Hospital Colorado;   University of Florida;   Alberta Children's Hospital;   M.D. Anderson Cancer Center;   Dana-Farber Cancer Institute;   Children's Mercy Hospital & Clinics;   All Children's Hospital;   Arnold Palmer Hospital for Children/MD Anderson Cancer Center Orlando
Recruiting - verified February 2012

Condition:   Malignant Thymoma
Intervention:   Drug: Milciclib Maleate
Sponsors:   Nerviano Medical Sciences;   Nerviano Medical Sciences
Recruiting - verified March 2012

Condition:   Chronic Lymphocytic Leukemia
Interventions:   Drug: bendamustine;   Drug: cyclophosphamide;   Drug: Fludarabine;   Drug: RO5072759
Sponsors:   Genentech;   Genentech
Recruiting - verified March 2012

Condition:   Prostatic Neoplasms
Interventions:   Drug: MDV3100;   Drug: Bicalutamide
Sponsors:   Astellas Pharma Inc;   Astellas Pharma Inc;   Medivation, Inc.
Recruiting - verified March 2012

Conditions:   Colonic Neoplasms;   Cancer of the Colon;   Colon Cancer;   Colon Neoplasms;   Colonic Cancer
Interventions:   Drug: Cetuximab;   Drug: AZD6244
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified October 2011

Conditions:   Leukemia;   Lymphoma;   Neuroblastoma;   Sarcoma;   Desmoplastic Small Round Cell Tumor
Interventions:   Drug: Melphalan;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Prednisone;   Drug: Vincristine;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Filgrastim;   Biological: NK-DLI Infusions
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Neoplasms
Intervention:   Drug: RO5185426
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified May 2012

Conditions:   Breast Cancer;   Depression;   Fatigue;   Sleep Disorders
Interventions:   Drug: metformin hydrochloride;   Genetic: DNA analysis;   Genetic: RNA analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: enzyme-linked immunosorbent assay;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Procedure: quality-of-life assessment
Sponsors:   National Cancer Institute (NCI);   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Advanced Endometrial Cancer
Intervention:   Drug: BKM120
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Conditions:   Infection;   Cancer;   Neoplasm;   Empyema;   Granuloma
Interventions:   Device: Xperguide CT;   Device: Electromagnetic Tracking;   Device: Computed Tomography
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institutes of Health Clinical Center (CC)
Recruiting - verified September 2011

Conditions:   Peripheral Neuropathic Pain;   Neurotoxicity;   Cancer
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Nursing Research (NINR)
Recruiting - verified October 2011

Condition:   Pancreatic Cancer
Interventions:   Drug: ICM plus Olaparib;   Drug: ICM without Olaparib
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified September 2011

Condition:   Cervical Cancer
Interventions:   Drug: cisplatin;   Drug: paclitaxel;   Drug: veliparib;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Cognitive/Functional Effects;   Colorectal Cancer;   Neurotoxicity
Interventions:   Biological: bevacizumab;   Drug: capecitabine;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin
Sponsors:   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B
Recruiting - verified February 2012

Condition:   Hepatocellular Carcinoma
Interventions:   Drug: ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol);   Drug: Placebo
Sponsors:   Polaris Group;   Polaris Group
Recruiting - verified March 2012

Conditions:   Carcinoma of Urinary Tract;   Urethral Carcinoma;   Carcinoma of Ureter;   Carcinoma of Renal Pelvis
Interventions:   Drug: Docetaxel;   Biological: Ramucirumab DP;   Biological: IMC-18F1
Sponsors:   ImClone LLC;   ImClone LLC
Recruiting - verified March 2012

Condition:   Patients With Chemotherapy Induced Anemia (CIA)
Intervention:   Drug: Monofer(R)
Sponsors:   Pharmacosmos A/S;   Pharmacosmos A/S
Recruiting - verified May 2011

Conditions:   Low Grade Glioma;   Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Oligoastrocytoma
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified September 2011

Condition:   Retinoblastoma
Intervention:   Drug: Melphalan hydrochloride
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified January 2012

Condition:   Breast Cancer
Interventions:   Biological: trastuzumab;   Drug: cyclophosphamide;   Drug: docetaxel;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel
Sponsors:   National Cancer Institute (NCI);   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Transplant-Related Cancer
Interventions:   Biological: Hepatitis A;   Biological: PCV 13
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Conditions:   Mesothelioma;   Pancreatic Cancer;   Ovarian Cancer;   Non-small Cell Lung Cancer
Intervention:   Drug: Amatuximab
Sponsors:   Morphotek;   Morphotek
Recruiting - verified January 2012

Conditions:   Brain and Central Nervous System Tumors;   Lymphoma;   Lymphoproliferative Disorder;   Small Intestine Cancer;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: imetelstat sodium;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Hormone Receptor-Positive Breast;   Gynecologic;   Desmoid;   Hormone Receptor-Positive Neoplasms
Interventions:   Drug: z-Endoxifen;   Drug: [(18)F] Fluoroestradiol
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified September 2011

Condition:   Pediatric Cancer
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institutes of Health Clinical Center (CC)
Recruiting - verified November 2011

Conditions:   Neoplasms;   Lymphomas
Intervention:   Drug: Belinostat
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified September 2011

Condition:   Breast Cancer
Interventions:   Drug: anastrozole;   Drug: exemestane;   Drug: letrozole;   Drug: systemic chemotherapy;   Drug: tamoxifen citrate
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions:   Drug: Hsp90 inhibitor STA-9090;   Other: laboratory biomarker analysis;   Genetic: polymerase chain reaction;   Other: enzyme-linked immunosorbent assay;   Genetic: RNA analysis;   Other: spectrophotometry;   Genetic: reverse transcriptase-polymerase chain reaction;   Genetic: gene expression analysis
Sponsors:   Barbara Ann Karmanos Cancer Institute;   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Melanoma (Skin)
Interventions:   Biological: ipilimumab;   Biological: recombinant interferon alfa-2b
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Cervical Cancer
Interventions:   Drug: brivanib alaninate;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Thyroid Cancer
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Advanced Solid Tumor With Peritoneal Carcinomatosis
Intervention:   Drug: veliparib in combination with low-dose fractionated whole abdominal radiation therapy
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Metastatic Renal Cell Carcinoma
Interventions:   Drug: Sunitinib;   Biological: IMA901 plus GM-CSF;   Drug: Cyclophosphamide
Sponsors:   immatics Biotechnologies GmbH;   immatics Biotechnologies GmbH
Recruiting - verified May 2012

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: Carboplatin/Paclitaxel/MEDI-575;   Drug: Carboplatin/Paclitaxel;   Drug: Carboplatin/Paclitaxel/MEDI-575
Sponsors:   MedImmune LLC;   MedImmune LLC
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Drug: cediranib maleate;   Drug: dasatinib
Sponsors:   National Cancer Institute (NCI);   Princess Margaret Hospital, Canada;   National Cancer Institute (NCI)
Recruiting - verified July 2011

Condition:   Malignant Melanoma
Intervention:   Drug: Lapatinib
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified August 2011

Conditions:   Solid Tumors;   Brain Tumors;   Brain Metastases
Intervention:   Drug: Satraplatin
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified October 2011

Condition:   Malignant Melanoma
Interventions:   Drug: RO5185426;   Drug: RO5185426;   Drug: RO5185426
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified May 2012

Conditions:   Mesolthelioma;   Esophageal Cancer;   Lung Cancer
Interventions:   Drug: Celecoxib;   Drug: ISCOMATRIX (TM) Adjuvant;   Biological: Autologous Tumor Cell Vaccine
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified January 2012

Conditions:   Lymphoma;   Nonneoplastic Condition
Interventions:   Genetic: DNA analysis;   Genetic: RNA analysis;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   AIDS Associated Malignancies Clinical Trials Consortium;   National Cancer Institute (NCI)
Recruiting - verified June 2011

Condition:   Head and Neck Cancer
Interventions:   Biological: cetuximab;   Drug: temsirolimus
Sponsors:   National Cancer Institute (NCI);   University of Chicago;   National Cancer Institute (NCI)
Recruiting - verified February 2011

Conditions:   Colorectal Neoplasms;   Digestive System Diseases;   Colonic Diseases;   Colorectal Cancer
Intervention:  
Sponsors:   Exact Sciences Corporation;   Exact Sciences Corporation
Recruiting - verified August 2011

Condition:   Relapsed Glioblastoma Multiforme
Intervention:   Drug: VB-111
Sponsors:   Vascular Biogenics Ltd. operating as VBL Therapeutics;   Vascular Biogenics Ltd. operating as VBL Therapeutics
Recruiting - verified November 2011

Condition:   Adrenal Cortex Neoplasms
Intervention:   Drug: Axitinib
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI);   Pfizer Pharmaceuticals, Inc.
Recruiting - verified July 2011

Condition:   Non-Small-Cell Lung Carcinoma
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified September 2011

Condition:   Herpes Zoster
Interventions:   Biological: V212;   Biological: Placebo
Sponsors:   Merck;   Merck
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Drug: Akt inhibitor MK2206;   Drug: bicalutamide;   Other: clinical observation
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Breast Neoplasms
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified August 2011

Condition:   Neoplasms
Interventions:   Drug: EZN-2208;   Drug: Bevacizumab
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified September 2010

Conditions:   Glioblastoma Multiforme;   Gliosarcoma;   Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Anaplastic Mixed Oligoastrocytoma
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified August 2011

Conditions:   Incurable Metastatic Colorectal Carcinoma;   Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Interventions:   Drug: PX-866 and cetuximab;   Drug: Cetuximab;   Drug: PX-866 and cetuximab;   Drug: Cetuximab
Sponsors:   Oncothyreon Inc.;   Oncothyreon Inc.
Recruiting - verified April 2012

Condition:   Leukemia
Interventions:   Biological: alemtuzumab;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dasatinib;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: etoposide phosphate;   Drug: fludarabine phosphate;   Drug: leucovorin calcium;   Drug: melphalan;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: vincristine sulfate;   Genetic: polymerase chain reaction;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Pleuropulmonary Blastoma;   Cystic Nephroma;   Ovarian Sertoli-Leydig Cell Tumors;   Ocular Medulloepithelioma;   Nasal Chondromesenchymal Hamartoma
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified August 2011

Condition:   Advanced Solid Tumors
Interventions:   Drug: MEDI3617;   Drug: MEDI3617 - Dose Expansion (CRC);   Drug: MEDI3617 - Dose Expansion (NSCLC);   Drug: MEDI3617 Single-Agent Optional Dose Expansion;   Drug: MEDI3617 + Bev Q3W Dose Escalation;   Drug: MEDI3617 + Bev Q2W Dose Escalation;   Drug: MEDI3617 + Bev Optional Dose Expansion;   Drug: MEDI3617 + Weekly Pax Dose Escalation;   Drug: MEDI3617 + Pax & Carbo Q3W Dos Esc;   Drug: MEDI3617 + Gem & Carbo Q3W Dos Esc
Sponsors:   MedImmune LLC;   MedImmune LLC
Recruiting - verified April 2012

Condition:   Leukemia
Interventions:   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: sorafenib tosylate;   Genetic: cytogenetic analysis;   Genetic: mutation analysis;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified September 2011

Condition:   Advanced Solid Tumors
Intervention:   Drug: ABT-806
Sponsors:   Abbott;   Abbott
Recruiting - verified March 2012

Conditions:   Myeloma;   Smoldering Multiple Myeloma
Intervention:   Drug: IHP2101 (anti-KIR)
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified August 2011

Condition:   Breast Cancer
Interventions:   Procedure: palliative surgery;   Procedure: therapeutic conventional surgery;   Radiation: palliative radiation therapy;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Advanced Myeloma.
Interventions:   Biological: Prevnar- Pneumococcal Conjugate Vaccine (PCV);   Other: Activated/costimulated autologous T-cell;   Drug: Lenalidomide;   Biological: MAGE-A3, Hiltonol® (Poly-ICLC)
Sponsors:   Abramson Cancer Center of the University of Pennsylvania;   Abramson Cancer Center of the University of Pennsylvania;   University of Pennsylvania
Recruiting - verified May 2012

Conditions:   Solid Tumor;   Anaplastic Thyroid Cancer
Interventions:   Drug: Cisplatin and Crolibulin;   Drug: Cisplatin
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified August 2011

Conditions:   Neoplasms;   Lymphoma
Intervention:   Drug: IPdR
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified August 2011

Condition:   Multiple Myeloma
Intervention:   Drug: Standard of Care
Sponsors:   Geron Corporation;   Geron Corporation
Recruiting - verified March 2012

Condition:   Prostate Cancer
Interventions:   Behavioral: telephone-based intervention;   Other: counseling intervention;   Other: educational intervention;   Procedure: therapeutic dietary intervention
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Colorectal Cancer
Interventions:   Procedure: Colonoscopy;   Procedure: FIT
Sponsors:   Department of Veterans Affairs;   Department of Veterans Affairs
Not yet recruiting - verified April 2012

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: vismodegib;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Pediatric Brain Tumor Consortium;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Stomach Cancer;   Esophageal Cancer
Interventions:   Biological: Ramucirumab;   Drug: Placebo;   Drug: Oxaliplatin;   Drug: Leucovorin;   Drug: 5-Fluorouracil
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified May 2012

Condition:   Prostate Cancer
Intervention:   Drug: 18F-DCFBC
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified August 2011

Conditions:   Mixed Muellerian Cancer;   Cervical Cancer;   Ovarian Cancer;   Breast Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer;   Endometrial Cancer;   Carcinosarcoma
Interventions:   Drug: Carboplatin;   Drug: Olaparib;   Drug: Treatment Effect
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified August 2011

Conditions:   Skin Cancer;   Metastatic Melanoma
Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Other: Gene Transfer
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified August 2011

Condition:   Chronic Myeloid Leukemia
Intervention:  
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   ICON Clinical Research
Recruiting - verified May 2012

Condition:   Multiple Myeloma
Interventions:   Procedure: Adoptive Immunotherapy;   Drug: Th1/Tc1 product
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI);   Hackensack University Medical Center
Recruiting - verified June 2011

Condition:   Breast Cancer
Interventions:   Drug: anastrozole;   Drug: entinostat;   Drug: tamoxifen citrate;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: therapeutic conventional surgery
Sponsors:   National Cancer Institute (NCI);   University of Chicago;   National Cancer Institute (NCI)
Recruiting - verified January 2011

Condition:   Prostate Cancer
Intervention:   Drug: tasquinimod
Sponsors:   Active Biotech AB;   Active Biotech AB
Recruiting - verified April 2012

Condition:   Leukemia
Interventions:   Drug: cytarabine;   Drug: dasatinib;   Drug: daunorubicin hydrochloride
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Pancreatic Cancer
Interventions:   Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   University of Colorado, Denver;   National Cancer Institute (NCI)
Recruiting - verified July 2011

Conditions:   Brain and Central Nervous System Tumors;   Kidney Cancer;   Sarcoma
Interventions:   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: topotecan hydrochloride;   Drug: vincristine sulfate
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Brain and Central Nervous System Tumors;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Small Intestine Cancer;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: Akt inhibitor MK2206;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Cancer;   Fatigue
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Nursing Research (NINR)
Recruiting - verified September 2011

Conditions:   Islet Cell Tumor;   Pancreatic Cancer
Interventions:   Biological: bevacizumab;   Drug: everolimus;   Drug: octreotide acetate
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Non Small Cell Lung Carcinoma
Interventions:   Drug: AZD6244;   Drug: Erlotinib;   Drug: AZD6244 + Erlotinib
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified July 2011

Condition:   Metastatic Pancreatic Adenocarcinoma
Intervention:   Drug: CO-1.01
Sponsors:   Clovis Oncology, Inc.;   Clovis Oncology, Inc.
Recruiting - verified March 2012

Conditions:   Myelodysplastic Syndromes;   MDS;   RAEB;   Chronic Myelomonocytic Leukemia
Intervention:   Drug: ON 01910.Na
Sponsors:   Onconova Therapeutics, Inc.;   Onconova Therapeutics, Inc.;   The Leukemia and Lymphoma Society
Recruiting - verified April 2012

Conditions:   Cognitive/Functional Effects;   Metastatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Procedure: cognitive assessment;   Procedure: quality-of-life assessment;   Radiation: intensity-modulated radiation therapy;   Radiation: whole-brain radiation therapy
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Prostate Neoplasms
Intervention:   Drug: ASG-5ME
Sponsors:   Astellas Pharma Inc;   Astellas Pharma Inc;   Seattle Genetics, Inc.
Recruiting - verified March 2012

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: lenalidomide;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   NCI - Pediatric Oncology Branch;   National Cancer Institute (NCI)
Recruiting - verified November 2011

Condition:   Endometrial Cancer
Intervention:   Drug: multitargeted tyrosine kinase inhibitor BIBF 1120
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Breast Cancer
Interventions:   Drug: BMS-754807;   Drug: letrozole
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Mayo Clinic
Recruiting - verified December 2011

Condition:   Colorectal Cancer
Interventions:   Drug: Panitumumab;   Drug: Oxaliplatin;   Drug: Irinotecan;   Drug: Leucovorin;   Drug: 5-Fluorouracil
Sponsors:   Sarah Cannon Research Institute;   Sarah Cannon Research Institute;   Amgen
Recruiting - verified July 2011

Conditions:   Sarcoma;   Neuroblastoma;   Wilms Tumor;   Leukemia;   Lymphoma;   Brain Tumors
Intervention:   Drug: Marqibo
Sponsors:   Talon Therapeutics, Inc;   Talon Therapeutics, Inc;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Neoplasms;   Nervous System Disease;   Vestibular Disease
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2012

Conditions:   Renal Cell Carcinoma;   Cancer
Interventions:   Drug: pazopanib;   Drug: placebo
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified May 2012

Condition:   Head and Neck Cancer
Interventions:   Drug: cisplatin;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Chronic Myelogenous Leukemia in Chronic Phase
Intervention:   Drug: nilotinib
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Conditions:   Diffuse Intrinsic Pontine Glioma;   Anaplastic Astrocytoma;   High Grade Glioma
Interventions:   Drug: Lenalidomide;   Radiation: Radiation Therapy
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified July 2011

Conditions:   Metastatic Cancer;   Metastatic Melanoma;   Renal Cancer
Interventions:   Genetic: Anti-VEGFR2 CAR CD8 plus PBL;   Drug: Cyclophosphamide;   Drug: Aldesleukin;   Drug: Fludarabine
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified August 2011

Conditions:   Lung Neoplasms;   Liver Neoplasms;   Kidney Neoplasms;   Cancer
Interventions:   Device: Laser-Assisted Angle Selection System;   Device: Block-Assisted Angle Selection System
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institutes of Health Clinical Center (CC)
Recruiting - verified March 2012

Conditions:   Prostate Neoplasms;   Genital Neoplasms, Male;   Urogenital Neoplasms;   Genital Diseases, Male
Intervention:   Drug: Abiraterone Acetate
Sponsors:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Available - verified April 2012

Condition:   Brain and Central Nervous System Tumors
Interventions:   Biological: bevacizumab;   Drug: irinotecan hydrochloride;   Drug: temozolomide
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Sarcoma
Interventions:   Biological: bevacizumab;   Drug: cyclophosphamide;   Drug: temsirolimus;   Drug: vinorelbine tartrate
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Non Small Cell Lung Cancer;   NSCLC
Interventions:   Drug: OSI-906;   Drug: Erlotinib;   Drug: Placebo
Sponsors:   Astellas Pharma Inc;   Astellas Pharma Inc
Recruiting - verified May 2012

Condition:   Sarcoma
Interventions:   Drug: ixabepilone;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Adenocarcinoma of the Lung
Interventions:   Biological: farletuzumab;   Other: Placebo;   Drug: Platinum Containing Doublet
Sponsors:   Morphotek;   Morphotek
Recruiting - verified May 2012

Condition:   Leukemia
Interventions:   Drug: Dasatinib;   Drug: BMS-833923
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified February 2012

Conditions:   Cancer;   Allogeneic Peripheral Blood Stem Cell Transplant;   Bone Marrow Transplantation
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Mental Health (NIMH)
Recruiting - verified July 2011

Condition:   Lymphoma
Interventions:   Biological: rituximab;   Drug: bendamustine hydrochloride;   Drug: bortezomib;   Drug: lenalidomide
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Endometrial Cancer
Intervention:   Biological: trebananib
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Metastatic Renal Cell Carcinoma
Interventions:   Drug: Dovitinib;   Drug: Sorafenib
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Condition:   Head and Neck Cancer
Interventions:   Drug: cediranib maleate;   Drug: lenalidomide
Sponsors:   National Cancer Institute (NCI);   University of Chicago;   National Cancer Institute (NCI)
Recruiting - verified October 2010

Condition:   Rectal Cancer
Intervention:   Radiation: High-dose endorectal brachytherapy
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified April 2012

Conditions:   Non Small Cell Lung Cancer (NSCLC);   Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions:   Drug: Docetaxel;   Drug: PX-866 and Docetaxel
Sponsors:   Oncothyreon Inc.;   Oncothyreon Inc.
Recruiting - verified March 2012

Condition:   Hematologic Malignancies
Interventions:   Other: Fludarabine, Cytoxan, TBI, Sirolimus;   Other: Fludarabine, Cytoxan, TBI, Sirolimus + MMF;   Other: Fludarabine, Cytoxan, TBI, Tacrolimus + MMF
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified January 2012

Conditions:   Bladder Neoplasm;   Intravesical Drug Administration;   Neoplasm Recurrence, Local;   Transitional Cell, Carcinoma;   Carcinoma in Situ;   Mycobacterium
Intervention:   Biological: EN3348
Sponsors:   Endo Pharmaceuticals;   Endo Pharmaceuticals
Recruiting - verified February 2012

Conditions:   Pancreatic Cysts;   Pancreatic Cancer
Intervention:  
Sponsors:   Johns Hopkins University;   Johns Hopkins University;   The Lustgarten Foundation
Recruiting - verified March 2012

Condition:   Kidney Cancer
Interventions:   Biological: bevacizumab;   Drug: everolimus;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Chordoma
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer
Interventions:   Biological: trastuzumab;   Drug: carboplatin;   Drug: paclitaxel
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Non-Small Cell Lung Neoplasms;   Prostate Neoplasms;   Bladder Neoplasms;   Ovarian Neoplasms;   Breast Neoplasms
Intervention:   Drug: MGAH22
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Mouth Neoplasms;   Head and Neck Neoplasms;   Tongue Neoplasms;   Carcinoma, Squamous Cell
Interventions:   Drug: Rapamycin;   Procedure: Biopsy;   Procedure: Dynamic CT Perfusion;   Procedure: Positron Emission Tomography;   Procedure: Measurement Serum Cytokines
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified February 2012

Conditions:   Ductal Carcinoma in Situ;   Estrogen Receptor-positive Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage I Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions:   Drug: letrozole;   Drug: zoledronic acid;   Other: laboratory biomarker analysis;   Other: enzyme-linked immunosorbent assay;   Other: mass spectrometry;   Procedure: bone scan;   Procedure: quality-of-life assessment;   Other: questionnaire administration;   Other: pharmacogenomic studies;   Other: high performance liquid chromatography
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified January 2012

Condition:   Prostate Cancer
Interventions:   Drug: Orteronel + prednisone;   Drug: Placebo + prednisone
Sponsors:   Millennium Pharmaceuticals, Inc.;   Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2012

Condition:   Prostate Cancer
Interventions:   Drug: Orteronel + prednisone;   Drug: Placebo + prednisone
Sponsors:   Millennium Pharmaceuticals, Inc.;   Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2012

Condition:   Lymphoma, Follicular
Interventions:   Biological: Ofatumumab;   Biological: Rituximab
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified May 2012

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cancer
Interventions:   Drug: AMG 386;   Drug: AMG 386 Placebo
Sponsors:   Amgen;   Amgen
Recruiting - verified May 2012

Conditions:   Lymphoma;   Nonneoplastic Condition
Interventions:   Biological: rituximab;   Drug: EPOCH regimen;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: vincristine sulfate;   Drug: vorinostat;   Other: R-CHOP regimen
Sponsors:   National Cancer Institute (NCI);   AIDS Associated Malignancies Clinical Trials Consortium;   National Cancer Institute (NCI)
Recruiting - verified August 2011

Condition:   Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: thioguanine;   Drug: vincristine sulfate
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Lymphoma
Intervention:   Biological: ofatumumab
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Thyroid Neoplasm
Intervention:   Drug: Valproic Acid
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified September 2011

Condition:   Prostate Cancer
Intervention:   Drug: GE-148 (18F)
Sponsors:   GE Healthcare;   GE Healthcare;   National Cancer Institute (NCI)
Recruiting - verified September 2011

Condition:   Colorectal Cancer
Interventions:   Biological: Ramucirumab;   Drug: Irinotecan;   Biological: Placebo;   Drug: Folinic Acid;   Drug: 5-Fluorouracil
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company;   ImClone LLC
Recruiting - verified May 2012

Condition:   Metastatic Liver Disease
Intervention:   Device: TheraSphere, Yttrium-90 glass Microspheres
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified January 2012

Conditions:   Metastatic Colorectal Cancer;   Metastatic Gastric Cancer;   Metastatic Pancreatic Cancer;   Metastatic Hepatocellular Carcinoma;   Metastatic Cholangiocarcinoma
Interventions:   Drug: CD8+ young TIL;   Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Estrogen Receptor Negative (ER-Negative) Breast Cancer;   Progesterone Receptor Negative (PR-Negative) Breast Cancer;   Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast Cancer;   Brain Metastases
Intervention:   Drug: INIPARIB + irinotecan
Sponsors:   Sanofi-Aventis;   Sanofi-Aventis;   UNC Lineberger Comprehensive Cancer Center
Recruiting - verified October 2011

Condition:   Prostate Cancer
Intervention:   Drug: ARN-509
Sponsors:   Aragon Pharmaceuticals, Inc.;   Aragon Pharmaceuticals, Inc.
Recruiting - verified March 2012

Condition:   Pediatric Acute Myelogenous Leukemia (AML)
Interventions:   Drug: Decitabine;   Drug: Decitabine
Sponsors:   Eisai Inc.;   Eisai Inc.
Recruiting - verified April 2012

Condition:   Solid Tumors
Intervention:   Drug: Sotatercept
Sponsors:   Celgene Corporation;   Celgene Corporation
Recruiting - verified December 2011

Condition:   Diffuse Large B-cell Lymphoma
Interventions:   Drug: Lenalidomide;   Drug: Gemcitabine;   Drug: Oxaliplatin;   Drug: Rituximab;   Drug: Etoposide
Sponsors:   Celgene Corporation;   Celgene Corporation
Recruiting - verified September 2010

Conditions:   Severe Aplastic Anemia;   MDS (Myelodysplastic Syndrome)
Interventions:   Device: Miltenyi CD34 Reagent System;   Other: Donor derived G-CSF mobilized PBC
Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012

Condition:   Non Small Cell Lung Cancer
Interventions:   Drug: Docetaxel;   Biological: Ramucirumab;   Drug: Placebo
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company;   ImClone LLC
Recruiting - verified May 2012

Conditions:   Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions:   Drug: panobinostat;   Drug: everolimus;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Other: liquid chromatography;   Other: mass spectrometry;   Other: enzyme-linked immunosorbent assay;   Other: immunohistochemistry staining method
Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute;   National Cancer Institute (NCI);   Novartis
Recruiting - verified April 2012

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: ruxolitinib phosphate;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Kidney Cancer
Interventions:   Drug: gemcitabine hydrochloride;   Drug: sunitinib malate
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified September 2011

Condition:   Neoplasms
Intervention:   Drug: RO5045337
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified May 2012

Conditions:   Leukemia;   Myelodysplastic Syndromes
Interventions:   Biological: anti-thymocyte globulin;   Drug: azacitidine;   Drug: busulfan;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: tacrolimus;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Soft Tissue Sarcoma
Interventions:   Drug: doxorubicin in combination with palifosfamide-tris;   Drug: doxorubicin in combination with placebo
Sponsors:   ZIOPHARM;   ZIOPHARM
Recruiting - verified April 2012

Condition:   Carcinoma, Squamous Cell of the Head and Neck
Interventions:   Biological: REOLYSIN;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Placebo
Sponsors:   Oncolytics Biotech;   Oncolytics Biotech
Recruiting - verified March 2012

Condition:   Ovarian Cancer
Interventions:   Drug: EC145;   Drug: Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®);   Drug: placebo;   Drug: EC20
Sponsors:   Endocyte;   Endocyte
Recruiting - verified March 2012

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Biological: 1121B (ramucirumab);   Drug: Pemetrexed;   Drug: Carboplatin (AUC 6);   Drug: Cisplatin;   Drug: Gemcitabine;   Drug: Carboplatin (AUC 5)
Sponsors:   ImClone LLC;   ImClone LLC
Recruiting - verified December 2011

Conditions:   Brain and Central Nervous System Tumors;   Childhood Germ Cell Tumor;   Kidney Cancer;   Leukemia;   Liver Cancer;   Neuroblastoma;   Sarcoma
Interventions:   Drug: alisertib;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Pleural Mesothelioma;   Peritoneal Mesothelioma
Intervention:   Drug: IMC-A12
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified January 2012

Conditions:   Minimal Residual Disease;   Leukemia, Lymphoblastic, Acute;   Leukemia, Myelogenous, Acute
Interventions:   Drug: Clofarabine;   Drug: Cytarabine;   Drug: Methotrexate;   Drug: Cytarabine
Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   Therapeutic Advances in Childhood Leukemia Consortium;   Genzyme
Recruiting - verified November 2011

Condition:   Colorectal Cancer
Interventions:   Drug: celecoxib;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Glioma
Intervention:   Drug: RAD001 (Everolimus)
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham;   Children's Hospital Boston;   Children's Hospital of Philadelphia;   Children's Research Institute;   Children's Hospital Medical Center, Cincinnati;   National Cancer Institute (NCI);   University of Chicago;   University of Utah;   Washington University School of Medicine
Recruiting - verified May 2012

Conditions:   Breast Cancer;   Gastric Cancer;   Bladder Cancer;   Ovarian Cancer;   Non-small Cell Lung Cancer
Intervention:   Biological: MGAH22
Sponsors:   MacroGenics;   MacroGenics;   Green Cross Corporation;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Prostate Cancer
Interventions:   Biological: fowlpox-PSA-TRICOM vaccine;   Biological: vaccinia-PSA-TRICOM vaccine;   Drug: docetaxel;   Drug: prednisone
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified September 2011

Conditions:   Lung Cancer;   Esophageal Cancer;   Malignant Pleural Mesothelioma;   Thymoma;   Thymic Carcinoma
Interventions:   Biological: Allogeneic Tumor Cell Vaccine (K562);   Drug: Celecoxib;   Drug: cyclophosphamide
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer
Interventions:   Biological: cixutumumab;   Drug: paclitaxel
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified June 2011

Conditions:   Breast Cancer;   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions:   Other: questionnaire administration;   Procedure: evaluation of cancer risk factors;   Procedure: quality-of-life assessment;   Procedure: study of high risk factors
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Small Lymphocytic Lymphoma;   CLL (Chronic Lymphocytic Leukemia)
Interventions:   Drug: Fludarabine Phosphate;   Biological: Ofatumumab;   Drug: Cyclophosphamide
Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI);   University of Virginia;   GlasoSmithKline
Recruiting - verified April 2012

Condition:   Prostate Cancer
Intervention:   Other: MRI examination
Sponsors:   Radboud University;   Radboud University;   Siemens AG;   Mount Vernon Hospital;   Multi-Imagem and CDPI, Rio de Janeiro, Brasil;   Norwegian University of Science and Technology;   University of California, Los Angeles;   University Hospital, Ghent;   Johns Hopkins University;   German Cancer Research Center;   Medical University of Vienna;   University Health Network, Toronto;   University of Heidelberg
Recruiting - verified July 2011

Condition:   Leukemia
Interventions:   Genetic: DNA ploidy analysis;   Genetic: chromosomal translocation analysis;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Other: cytology specimen collection procedure;   Other: flow cytometry;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Lymphoma;   HIV
Intervention:   Procedure: Autologous transplant
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network
Recruiting - verified January 2012

Condition:   Leukemia
Interventions:   Drug: temozolomide;   Drug: veliparib;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   University of Chicago;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Neoplasm Malignant
Intervention:   Drug: Cabazitaxel (XRP6258)
Sponsors:   Sanofi-Aventis;   Sanofi-Aventis
Recruiting - verified May 2012

Condition:   Endometrial Cancer
Interventions:   Drug: cediranib maleate;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified November 2011

Conditions:   HLRCC;   Metastatic Papillary RCC
Interventions:   Drug: Bevacizumab;   Drug: Erlotinib
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified December 2011

Condition:   Non-Metastatic Adenocarcinoma of the Rectum
Interventions:   Procedure: Radiation Therapy;   Drug: Capecitabine;   Drug: AZD6244
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified December 2011

Condition:   Metastatic Renal Cell Carcinoma
Interventions:   Drug: E7080;   Drug: Everolimus;   Drug: E7080 plus Everolimus
Sponsors:   Eisai Inc.;   Eisai Inc.
Recruiting - verified April 2012

Condition:   Lymphoma
Interventions:   Biological: bleomycin sulfate;   Drug: ABVD regimen;   Drug: BEACOPP regimen;   Drug: cyclophosphamide;   Drug: dacarbazine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vinblastine sulfate;   Drug: vincristine sulfate;   Other: laboratory biomarker analysis;   Procedure: computed tomography;   Radiation: fludeoxyglucose F 18;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Thrombocytopaenia
Interventions:   Drug: Eltrombopag olamine;   Other: Placebo
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified April 2012

Condition:   Leukemia
Interventions:   Drug: clofarabine;   Drug: entinostat;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   Breast Cancer
Interventions:   Drug: tamoxifen citrate;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Non-small-cell Lung Cancer
Intervention:   Drug: AUY922
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Conditions:   Stage IIIC Melanoma;   Stage IV Melanoma
Intervention:   Drug: Denileukin diftitox
Sponsors:   Eisai Inc.;   Eisai Inc.;   PharmaBio Development Inc.
Recruiting - verified May 2012

Condition:   Acromegaly
Interventions:   Drug: Pasireotide (SOM230);   Drug: octreotide LAR 30mg or lanreotide ATG 120mg
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified November 2011

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: gamma-secretase inhibitor RO4929097;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: adjuvant therapy;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Non Small Cell Lung Cancer
Interventions:   Drug: COMBINED PF-02341066 AND PF-00299804;   Drug: PF-00299804 FOLLOWED BY COMBINED PF-02341066 AND PF-00299804
Sponsors:   Pfizer;   Pfizer
Recruiting - verified May 2012

Condition:   Breast Neoplasms
Interventions:   Drug: BIBW 2992;   Drug: trastuzumab;   Drug: vinorelbine;   Drug: vinorelbine
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012

Condition:   Kidney Cancer
Interventions:   Drug: everolimus;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Medulloblastoma,;   Rhabdomyosarcoma,;   Neuroblastoma,;   Hepatoblastoma,;   High Grade Glioma,;   Astrocytoma
Intervention:   Drug: LDE225
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Conditions:   Neoplasms;   Liver Metastases
Intervention:   Drug: EZN-2968
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified December 2011

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions:   Biological: EGEN-001;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Acute Myelogenous Leukemia;   Diffuse Large B-Cell Leukemia;   Chronic Lymphocytic Leukemia;   Follicular Lymphoma
Interventions:   Drug: BMS-936564 (Anti-CXCR4);   Drug: BMS-936564 (Anti-CXCR4)
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified December 2011

Conditions:   Pediatric Cancer;   Leukemia;   Sarcoma;   Brain Tumors
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified January 2012

Conditions:   Ovarian Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer
Interventions:   Drug: cediranib;   Drug: olaparib
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Massachusetts General Hospital;   Beth Israel Deaconess Medical Center;   University of Chicago;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Breast Cancer
Interventions:   Drug: trastuzumab emtansine;   Drug: pertuzumab;   Drug: pertuzumab-placebo;   Drug: trastuzumab [Herceptin];   Drug: docetaxel;   Drug: paclitaxel
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche;   Genentech
Recruiting - verified March 2012

Conditions:   Ependymoma;   Brainstem Glioma;   Astrocytoma;   Glioblastoma Multiforme;   PNET
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified February 2011

Condition:   Lymphoma
Interventions:   Biological: bleomycin sulfate;   Drug: ABVD regimen;   Drug: BEACOPP regimen;   Drug: cyclophosphamide;   Drug: dacarbazine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vinblastine sulfate;   Drug: vincristine sulfate;   Other: laboratory biomarker analysis;   Procedure: computed tomography;   Radiation: fludeoxyglucose F 18;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Monoclonal B-Cell Lymphocytosis
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI);   North Shore Long Island Jewish Health System
Recruiting - verified January 2012

Conditions:   Sarcoma;   Endocrine Tumors;   Neuroblastoma;   Retinoblastoma;   Renal Cancer
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified December 2011

Condition:   Non-Medullary Thyroid Cancer
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified December 2011

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Drug: pemetrexed disodium
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Smoldering Myeloma;   Monoclonal Gammopathy of Undetermined Significance
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified December 2011

Conditions:   Bone Metastases;   Castration-Resistant Prostate Cancer
Interventions:   Drug: Alpharadin® (Radium-223 chloride) + docetaxel;   Drug: Docetaxel
Sponsors:   Algeta ASA;   Algeta ASA;   Bayer
Recruiting - verified October 2011

Condition:   Breast Cancer
Interventions:   Drug: letrozole;   Drug: panobinostat;   Genetic: RNA analysis;   Genetic: microarray analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: enzyme-linked immunosorbent assay;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Solid Tumor Malignancies
Intervention:   Biological: Clostridium novyi-NT spores
Sponsors:   BioMed Valley Discoveries, Inc;   BioMed Valley Discoveries, Inc
Recruiting - verified November 2011

Condition:   Breast Cancer
Interventions:   Drug: metformin hydrochloride;   Other: placebo
Sponsors:   NCIC Clinical Trials Group;   NCIC Clinical Trials Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Cervical Cancer
Interventions:   Drug: cisplatin;   Radiation: external beam radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   NSCLC;   Solid Tumors
Interventions:   Drug: YM155;   Drug: Carboplatin;   Drug: Paclitaxel
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified August 2011

Conditions:   Chemotherapeutic Agent Toxicity;   Colorectal Cancer;   Neuropathy;   Neurotoxicity
Interventions:   Drug: calcium gluconate;   Drug: magnesium sulfate;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: vincristine sulfate;   Other: clinical observation;   Radiation: 3-dimensional conformal radiation therapy
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Disease, Hodgkin
Interventions:   Drug: brentuximab vedotin;   Drug: placebo
Sponsors:   Seattle Genetics, Inc.;   Seattle Genetics, Inc.;   Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012

Conditions:   Prostate Cancer;   Metastatic Castrate Resistant Prostate Cancer
Intervention:   Drug: TRC105
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified September 2011

Conditions:   Thymoma;   Thymic Carcinoma
Interventions:   Drug: Belinostat;   Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified November 2011

Condition:   Brain and Central Nervous System Tumors
Intervention:   Drug: AZD6244
Sponsors:   Pediatric Brain Tumor Consortium;   Pediatric Brain Tumor Consortium;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Bladder Cancer
Intervention:   Device: Neo-Urinary Conduit
Sponsors:   Tengion;   Tengion
Recruiting - verified January 2012

Conditions:   Burkitt Lymphoma;   Diffuse Large B-cell Lymphoma, c-MYC Positive
Interventions:   Drug: rituximab;   Drug: etoposide;   Drug: cyclophosphamide;   Drug: doxorubicin;   Drug: vincristine;   Drug: prednisone;   Drug: filgrastim
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified September 2011

Conditions:   Chronic Lymphocytic Leukemia;   Lymphoma, Non-Hodgkin;   Acute Myeloid Leukemia;   Multiple Myeloma
Intervention:   Drug: CAL-101
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified January 2012

Condition:   B Cell Malignancies
Intervention:   Genetic: Anti-CD19-CAR-transduced T cells
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Breast Cancer;   Lung Cancer;   Renal Cancer;   Adrenal Cancer
Intervention:   Drug: F-18 Paclitaxel (FPAC)
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Not yet recruiting - verified September 2011

Conditions:   Hairy Cell Leukemia (HCL);   Chronic Lymphocytic Leukemia (CLL);   Non-Hodgkins Lymphoma (NHL);   Cutaneous T Cell Lymphoma (CTCL);   Adult T Cell Lymphoma (ATL)
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified September 2011

Conditions:   Autism;   Tuberous Sclerosis
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified December 2011

Conditions:   Head and Neck Cancer;   Precancerous Condition
Interventions:   Biological: cetuximab;   Radiation: intensity-modulated radiation therapy
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified June 2011

Condition:   Prostate Cancer
Interventions:   Drug: Testosterone;   Drug: Etoposide
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified May 2012

Condition:   Malignant Pleural Mesothelioma
Interventions:   Drug: NGR-hTNF plus Best Investigator Choice (BIC);   Drug: Placebo plus Best Investigator Choice (BIC)
Sponsors:   MolMed S.p.A.;   MolMed S.p.A.
Recruiting - verified December 2011

Condition:   Squamous Cell Lung Cancer
Interventions:   Drug: gemcitabine/carboplatin;   Drug: gemcitabine/carboplatin plus Iniparib
Sponsors:   Sanofi-Aventis;   Sanofi-Aventis;   BiPar Sciences
Recruiting - verified March 2012

Condition:   Breast Cancer
Interventions:   Other: circulating tumor cell analysis;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Procedure: adjuvant therapy;   Radiation: 3-dimensional conformal accelerated partial breast irradiation
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified July 2011

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer
Interventions:   Biological: bevacizumab;   Drug: capecitabine;   Drug: carboplatin;   Drug: oxaliplatin;   Drug: paclitaxel;   Procedure: quality-of-life assessment
Sponsors:   University College, London;   University College, London;   National Cancer Institute (NCI);   Gynecologic Oncology Group
Recruiting - verified December 2011

Condition:   Malignant Mesothelioma
Interventions:   Drug: pemetrexed disodium;   Other: clinical observation
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   Colorectal Cancer
Interventions:   Biological: cetuximab;   Biological: ramucirumab;   Drug: irinotecan hydrochloride
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Indolent Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia;   Mantle Cell Lymphoma
Interventions:   Drug: CAL-101;   Drug: Rituximab;   Drug: Bendamustine;   Drug: Ofatumumab;   Drug: Fludarabine;   Drug: Everolimus;   Drug: Bortezomib;   Drug: Chlorambucil
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified April 2012

Conditions:   Chronic Lymphocytic Leukemia (CLL);   Diffuse Large B-Cell Lymphoma (DLBCL);   Non-Hodgkin's Lymphoma (NHL);   Follicular Lymphoma (FL);   Mantle Cell Lymphoma (MCL)
Intervention:   Drug: CAT-8015
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified September 2011

Condition:   Metastatic Pancreatic Cancer
Intervention:   Drug: Gemcitabine, nab-Paclitaxel, GDC-0449
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   Stand Up To Cancer;   Genentech;   Celgene Corporation
Recruiting - verified March 2012

Condition:   Multiple Myeloma
Intervention:  
Sponsors:   Celgene Corporation;   Celgene Corporation
Recruiting - verified June 2011

Conditions:   Cancer;   Pain
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institutes of Health Clinical Center (CC)
Recruiting - verified June 2011

Condition:   Chronic Lymphocytic Leukemia
Intervention:  
Sponsors:   Celgene Corporation;   Celgene Corporation
Recruiting - verified March 2011

Condition:   Advanced Malignancies
Intervention:   Drug: INCB028060
Sponsors:   Incyte Corporation;   Incyte Corporation;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Condition:   Lymphoma
Interventions:   Drug: lenalidomide;   Drug: temsirolimus;   Other: enzyme-linked immunosorbent assay;   Other: flow cytometry;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   University of Chicago;   National Cancer Institute (NCI)
Recruiting - verified November 2010

Conditions:   Lymphoma, Non-Hodgkin;   Lymphoma, Follicular
Interventions:   Drug: Ofatumumab and Bendamustine infusions (Arm A);   Drug: Bendamustine infusion (Arm B)
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified March 2012

Condition:   Cancer
Interventions:   Drug: GSK2118436;   Drug: GSK1120212
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified December 2011

Condition:   Breast Cancer
Interventions:   Drug: Placebo;   Drug: Denosumab
Sponsors:   Amgen;   Amgen;   Daiichi Sankyo Inc.
Recruiting - verified May 2012

Condition:   Malignant Solid Tumour
Intervention:   Drug: AZD6244 and IMC-A12
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified May 2012

Condition:   Renal Cell Carcinoma
Intervention:   Drug: Sunitinib and Dalteparin mono and combination therapy
Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute;   Pfizer
Recruiting - verified March 2012

Condition:   Prostate Cancer
Interventions:   Drug: Ipilimumab;   Drug: Placebo
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified March 2012

Condition:   Lung Cancer
Interventions:   Radiation: prophylactic cranial irradiation;   Radiation: selective external radiation therapy
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Hairy Cell Leukemia
Interventions:   Drug: Pentostatin;   Drug: Rituximab;   Drug: Bendamustine
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified August 2011

Condition:   Non-Hodgkin's Lymphoma
Interventions:   Drug: bendamustine;   Drug: RO5072759
Sponsors:   Genentech;   Genentech;   Roche Pharma AG
Recruiting - verified May 2012

Conditions:   Nonneoplastic Condition;   Sarcoma
Interventions:   Drug: lenalidomide;   Other: laboratory biomarker analysis
Sponsors:   AIDS Malignancy Clinical Trials Consortium;   AIDS Malignancy Clinical Trials Consortium;   National Cancer Institute (NCI)
Recruiting - verified December 2011

Conditions:   Neoplasms;   Lymphoma
Interventions:   Drug: LMP 400;   Drug: LMP 776
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   Sarcoma
Interventions:   Biological: cixutumumab;   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: irinotecan hydrochloride;   Drug: temozolomide;   Drug: vincristine sulfate
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Ovarian Cancer;   Non Small Cell Lung Cancer;   Prostate Cancer;   Colorectal Cancer;   Gastric Cancer;   Esophageal Cancer;   Cancer of Head and Neck
Interventions:   Drug: LY2523355;   Drug: pegfilgrastim
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified May 2012

Condition:   Lung Cancer
Interventions:   Drug: carboplatin;   Drug: celecoxib;   Drug: gemcitabine hydrochloride;   Drug: pemetrexed disodium;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Non-Small-Cell Lung Cancer
Interventions:   Drug: Carboplatin;   Drug: Pemetrexed;   Drug: Panitumumab
Sponsors:   Sarah Cannon Research Institute;   Sarah Cannon Research Institute;   Amgen
Recruiting - verified October 2011

Conditions:   Metastatic Pancreatic Cancer;   Metastatic Colorectal Cancer
Intervention:   Drug: NPC-1C
Sponsors:   Neogenix Oncology, Inc.;   Neogenix Oncology, Inc.
Recruiting - verified January 2012

Condition:   Leukemia
Interventions:   Drug: clofarabine;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: decitabine;   Other: clinical observation
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Carcinoma
Interventions:   Drug: Pazopanib;   Drug: Doxil
Sponsors:   Sarah Cannon Research Institute;   Sarah Cannon Research Institute;   GlaxoSmithKline
Recruiting - verified November 2011

Condition:   Renal Cell Carcinoma
Intervention:   Drug: Aldesleukin
Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute
Recruiting - verified January 2012

Condition:   Metastatic Breast Cancer
Intervention:   Drug: Amrubicin
Sponsors:   Sarah Cannon Research Institute;   Sarah Cannon Research Institute;   Celgene Corporation
Recruiting - verified July 2011

Condition:   Multiple Myeloma
Interventions:   Biological: aMILs;   Biological: Allogeneic Myeloma Vaccine
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified January 2012

Condition:   Carcinoma
Intervention:   Drug: Everolimus
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified March 2012

Conditions:   WT1-positive Acute Myeloid Leukemia;   Leukaemia, Myelocytic, Acute
Intervention:   Biological: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2130579A
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified March 2012

Condition:   Recurrent or Refractory Pediatric Ependymoma
Interventions:   Drug: erlotinib;   Drug: etoposide
Sponsors:   OSI Pharmaceuticals;   OSI Pharmaceuticals;   Astellas Pharma Global Development, Inc.
Recruiting - verified February 2012

Conditions:   Hodgkin Lymphoma;   Diffuse Large B-Cell Lymphoma
Interventions:   Drug: Cylcophosphamide;   Drug: Etoposide;   Drug: Alemtuzumab;   Drug: Doxorubicin;   Drug: Prednisone;   Drug: Filgrastim;   Drug: Rituximab;   Drug: Vincristine
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Melanoma
Intervention:   Drug: nilotinib (AMN107)
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified May 2012

Condition:   Lymphoma
Interventions:   Drug: Bendamustine;   Drug: Bortezomib;   Drug: Rituximab
Sponsors:   Sarah Cannon Research Institute;   Sarah Cannon Research Institute;   Millennium Pharmaceuticals, Inc.;   Cephalon
Recruiting - verified July 2011

Condition:   Multiple Myeloma
Intervention:   Biological: BI-505
Sponsors:   BioInvent International AB;   BioInvent International AB
Recruiting - verified January 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Panobinostat;   Drug: Bortezomib
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Conditions:   Leukemia;   Lymphoma
Interventions:   Biological: anti-thymocyte globulin;   Biological: rituximab;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: sirolimus;   Drug: tacrolimus;   Other: laboratory biomarker analysis;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Melanoma;   Carcinoma, Renal Cell
Intervention:   Drug: Recombinant Human IL-15
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Lung Cancer
Interventions:   Biological: Seneca Valley virus-001;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   Liver Cancer
Interventions:   Drug: doxorubicin hydrochloride;   Drug: sorafenib tosylate
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified September 2011

Condition:   Pancreatic Cancer
Interventions:   Drug: capecitabine;   Drug: erlotinib hydrochloride;   Drug: fluorouracil;   Drug: gemcitabine hydrochloride;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Brain Cancer
Intervention:   Other: cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Children's Healthcare of Atlanta;   Dana-Farber Cancer Institute;   M.D. Anderson Cancer Center;   Phoenix Children's Hospital;   Alberta Children's Hospital;   University of Colorado, Denver;   Seattle Children's Hospital;   Johns Hopkins University;   Children's Mercy Hospital-Kansas City, MO;   MD Anderson Cancer Center Orlando at Arnold Palmer Hospital for Children
Recruiting - verified March 2012

Conditions:   Colorectal Cancer;   Precancerous Condition
Interventions:   Drug: rosuvastatin;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Advanced Solid Tumors
Intervention:   Drug: XMT-1107
Sponsors:   Mersana Therapeutics;   Mersana Therapeutics
Recruiting - verified September 2011

Condition:   Sarcoma
Interventions:   Drug: bortezomib;   Genetic: RNA analysis;   Genetic: gene expression analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
Sponsors:   AIDS Malignancy Clinical Trials Consortium;   AIDS Malignancy Clinical Trials Consortium;   National Cancer Institute (NCI)
Recruiting - verified November 2011

Conditions:   Breast Cancer;   Cardiac Toxicity
Interventions:   Drug: carvedilol phosphate extended-release capsule;   Drug: lisinopril;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   University of South Florida;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Liver Cancer
Interventions:   Biological: cixutumumab;   Drug: sorafenib tosylate;   Other: laboratory biomarker analysis
Sponsors:   California Cancer Consortium;   California Cancer Consortium;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Sarcoma
Interventions:   Biological: bevacizumab;   Biological: filgrastim;   Biological: pegfilgrastim;   Drug: docetaxel;   Drug: gemcitabine hydrochloride;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   HER2/Neu Over-expressing Locally Advanced Breast Cancer;   Metastatic Breast Cancer
Interventions:   Drug: everolimus, vinorelbine, trastuzumab;   Drug: Placebo + vinorelbine + trastuzumab
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified May 2012

Condition:   Thymic Carcinoma
Intervention:   Drug: Milciclib Maleate
Sponsors:   Nerviano Medical Sciences;   Nerviano Medical Sciences
Recruiting - verified March 2012

Conditions:   Neuroendocrine Neoplasms;   Thyroid Neoplasms;   Parathyroid Neoplasms;   Adrenal Neoplasm;   Neuroblastoma
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified June 2011